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Summary 
Hepatitis B vaccination is the most effective measure to prevent hepatitis B virus (HBV) infection and its consequences, 
including cirrhosis of the liver, liver cancer, liver failure, and death. In adults, ongoing HBV transmission occurs primarily among 
unvaccinated persons with behavioral risks for HBV transmission (e.g., heterosexuals with multiple sex partners, injection-drug 
users [IDUs], and men who have sex with men [MSM]) and among household contacts and sex partners of persons with chronic 
HBV infection. 
This report, the second of a two-part statement from the Advisory Committee on Immunization Practices (ACIP), provides 
updated recommendations to increase hepatitis B vaccination of adults at risk for HBV infection. The first part of the ACIP 
statement, which provided recommendations for immunization of infants, children, and adolescents, was published previously 
(CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: 
recommendations of the Advisory Committee on Immunization Practices [ACIP]. Part 1: immunization of infants, children, 
and adolescents. MMWR 2005;54[No. RR-16]:1–33). 
In settings in which a high proportion of adults have risks for HBV infection (e.g., sexually transmitted disease/human immu­
nodeficiency virus testing and treatment facilities, drug-abuse treatment and prevention settings, health-care settings targeting 
services to IDUs, health-care settings targeting services to MSM, and correctional facilities), ACIP recommends universal hepati­
tis B vaccination for all unvaccinated adults. In other primary care and specialty medical settings in which adults at risk for HBV 
The material in this report originated in the National Center for HIV/ 
AIDS, Viral Hepatitis, STD, and TB Prevention (proposed), Kevin 
A. Fenton, MD, PhD, Director; the Division of Viral Hepatitis, John 
W. Ward, MD, Director; the Division of STD Prevention, John M. 
Douglas, Jr., MD, Director; and the Division of HIV/AIDS 
Prevention, Robert S. Janssen, MD, Director; the National Center 
for Immunization and Respiratory Diseases, Anne Schuchat, MD, 
Director; and the Immunization Services Division, Lance E. Rodewald, 
MD, Director. 
Corresponding preparer: Eric E. Mast, MD, Division of Viral 
Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and 
TB Prevention (proposed), 1600 Clifton Road, NE, MS G-37, Atlanta, 
GA 30333. Telephone: 404-718-8500; Fax: 404-718-8595; E-mail: 
emast@cdc.gov. 
infection receive care, health-care providers should inform all 
patients about the health benefits of vaccination, including 
risks for HBV infection and persons for whom vaccination is 
recommended, and vaccinate adults who report risks for HBV 
infection and any adults requesting protection from HBV 
infection. To promote vaccination in all settings, health-care 
providers should implement standing orders to identify adults 
recommended for hepatitis B vaccination and administer vac­
cination as part of routine clinical services, not require 
acknowledgment of an HBV infection risk factor for adults to 
receive vaccine, and use available reimbursement mechanisms 
to remove financial barriers to hepatitis B vaccination. 
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Introduction 
Hepatitis B is a disease caused by the hepatitis B virus (HBV), 
which is transmitted through percutaneous (i.e., puncture 
through the skin) or mucosal (i.e., direct contact with 
mucous membranes) exposure to infectious blood or body flu­
ids. HBV can cause chronic infection, resulting in cirrhosis of 
the liver, liver cancer, liver failure, and death. Persons with 
chronic infection also serve as the main reservoir for continued 
HBV transmission. Although chronic infection is more likely 
to develop in persons infected as infants or young children, 
rates of new infection and acute disease are highest among adults. 
Hepatitis B vaccination is the most effective measure to pre­
vent HBV infection and its consequences. Since recommen­
dations for hepatitis B vaccination were first issued in 1982, a 
comprehensive strategy to eliminate HBV transmission in the 
United States has evolved (1–5). This strategy includes 
1) universal vaccination of infants beginning at birth, 2) pre­
vention of perinatal HBV infection through routine screening 
of all pregnant women for hepatitis B surface antigen (HBsAg) 
and postexposure immunoprophylaxis of infants born to 
HBsAg-positive women or to women with unknown HBsAg 
status, 3) vaccination of all children and adolescents who were 
not vaccinated previously, and 4) vaccination of previously 
unvaccinated adults at risk for HBV infection (Box 1). 
To date, immunization strategies for infants, children, and 
adolescents have been implemented with considerable suc­
cess. Recent estimates indicate that approximately 95% of 
pregnant women are tested for HBsAg and that case manage­
ment has been effective in ensuring high levels of initiation 
and completion of postexposure immunoprophylaxis among 
infants born to HBsAg-positive women (6). Hepatitis B vac­
cine has been integrated successfully into the childhood vac­
cination schedule, and infant vaccination coverage levels now 
are equivalent to those of other vaccines in the childhood 
BOX 1. Immunization strategy to eliminate transmission of 
hepatitis B virus (HBV) in the United States 
• Universal vaccination of infants beginning at birth 
• Prevention of perinatal HBV infection through 
—	 routine screening of all pregnant women for 
hepatitis B surface antigen (HBsAg), and 
—	 immunoprophylaxis of infants born to HBsAg­
positive women or to women with unknown HBsAg 
status 
• Routine vaccination of previously unvaccinated children 
and adolescents 
• Vaccination of previously unvaccinated adults at risk 
for HBV infection 
schedule (7). Vaccination coverage among adolescents also has 
increased substantially; preliminary data from 2003 indicated 
that approximately 50%–60% of adolescents aged 13–15 years 
have records indicating vaccination (with 3 doses) against hepa­
titis B (8). During 1990–2005, incidence of acute hepatitis B 
in the United States declined 78%. The greatest decline (96%) 
occurred among children and adolescents, coincident with an 
increase in hepatitis B vaccination coverage. This success can 
be attributed in part to the established infrastructure for vac­
cine delivery to children and to federal support for perinatal 
hepatitis B prevention programs. 
Among adults, ongoing HBV transmission occurs prima­
rily among unvaccinated adults with risk behaviors for HBV 
transmission (e.g., heterosexuals with multiple sex partners, 
injection-drug users [IDUs], and men who have sex with men 
[MSM]) and among household contacts and sex partners of 
persons with chronic HBV infection. During 2000–2004, self-
reported hepatitis B vaccination coverage among adults at risk 
for HBV infection increased from 30% to 45% (9); this 
increase in vaccination coverage likely contributed to the 35% 
decline in acute hepatitis B incidence that occurred during 
this period (from 3.7 to 2.4 per 100,000 population). How­
ever, incidence of acute hepatitis B remains highest among 
adults, who accounted for approximately 95% of an estimated 
51,000 new HBV infections in 2005. Although acceptance of 
vaccination is high among adults offered vaccination (10), 
the low adult vaccination coverage reflects the lack of hepati­
tis B vaccination services in settings in which a high propor­
tion of adults have risk factors for HBV infection (e.g., sexually 
transmitted disease [STD]/human immunodeficiency virus 
[HIV] testing and treatment facilities, drug-abuse treatment 
and prevention settings, health-care settings targeting services 
to IDUs, health-care settings targeting services to MSM, and 
correctional facilities) and missed opportunities to vaccinate 
adults at risk for HBV infection in primary care and specialty 
medical settings. Although hepatitis B incidence among adults 
is expected to continue to decline during the next decade as 
successive cohorts of persons vaccinated in infancy, childhood, 
and adolescence reach adulthood, new implementation strat­
egies are needed to protect unvaccinated adults at risk for HBV 
infection. 
This report provides updated guidance from the Advisory 
Committee on Immunization Practices (ACIP) to increase hepa­
titis B vaccination coverage among adults. It includes recom­
mendations regarding which adults should receive hepatitis B 
vaccine and outlines implementation strategies to ensure that 
those adults are vaccinated. The first part of this statement, 
which provided recommendations for immunization of infants, 
children, and adolescents, was published previously (11). 
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Methods 
In response to continuing low rates of hepatitis B vaccina­
tion among adults at risk for HBV infection, ACIP’s Hepati­
tis Vaccines Work Group met multiple times during October 
2004–September 2005 to review previous guidelines and make 
recommendations for improving vaccination coverage in 
adults. The work group examined the progress made since 
1991 in implementing the U.S. strategy to eliminate HBV 
transmission (e.g., vaccination coverage data and hepatitis B 
disease rates), surveillance data on missed opportunities for 
hepatitis B vaccination among adults with acute hepatitis B, 
and results of cost-effectiveness analyses. In addition, demon­
stration projects conducted in settings in which a high pro­
portion of clients were at risk for HBV infection identified 
the components of successful adult hepatitis B vaccination 
programs and ongoing challenges to implementing adult hepa­
titis B vaccination. 
In January 2005, the proposed recommendations were 
posted online for public comment. In May 2005, CDC con­
vened a meeting of external consultants, including research­
ers, physicians, state and local public health professionals, 
immunization program directors, and directors of viral hepa­
titis, STD, and HIV/AIDS prevention programs, to obtain 
input into the draft recommendations and consider the feasi­
bility of the recommended strategies. In October 2005, the 





This report updates ACIP recommendations published pre­
viously for hepatitis B vaccination of adults (3). The primary 
changes from previous recommendations are as follows: 
• In settings in which a high proportion of persons are likely 
to be at risk for HBV infection (e.g., STD/HIV testing 
and treatment facilities, drug-abuse treatment and pre­
vention settings, health-care settings targeting services to 
IDUs, health-care settings targeting services to MSM, and 
correctional facilities), ACIP recommends universal hepa­
titis B vaccination for all adults who have not completed 
the vaccine series. 
• In primary care and specialty medical settings, ACIP rec­
ommends implementation of standing orders to identify 
adults recommended for hepatitis B vaccination and 
administer vaccination as part of routine services. To 
ensure vaccination of adults at risk for HBV infection 
who have not completed the vaccine series, ACIP recom­
mends the following implementation strategies: 
— Provide information to all adults regarding the health 
benefits of hepatitis B vaccination, including risk fac­
tors for HBV infection and persons for whom vacci­
nation is recommended. 
— Help all adults assess their need for vaccination by 
obtaining a history that emphasizes risks for sexual 
transmission and percutaneous or mucosal exposure 
to blood. 
— Vaccinate all adults who report risks for HBV infection. 
— Vaccinate all adults requesting protection from HBV 
infection, without requiring them to acknowledge a 
specific risk factor. 
Background 
Clinical Features and Natural History 
of HBV Infection 
HBV is a 42-nm DNA virus classified in the Hepadnaviridae 
family. The liver is the primary site of HBV replication. After 
a susceptible person is exposed, the virus enters the liver via 
the bloodstream; no evidence exists indicating that the virus 
replicates at mucosal surfaces. HBV infection can produce 
either asymptomatic or symptomatic infection. The average 
incubation period is 90 days (range: 60–150 days) from 
exposure to onset of jaundice and 60 days (range: 40–90 days) 
from exposure to onset of abnormal serum alanine aminotrans­
ferase (ALT) levels (12,13). 
The onset of acute disease typically is insidious. Infants, 
children aged <5 years, and immunosuppressed adults with 
newly acquired HBV infection typically are asymptomatic, 
whereas 30%–50% of children aged >5 years and adults have 
initial clinical signs or symptoms (14). When present, clinical 
symptoms and signs can include anorexia, malaise, nausea, 
vomiting, abdominal pain, and jaundice. Extrahepatic mani­
festations of disease (e.g., skin rashes, arthralgias, and arthri­
tis) also can occur (15). The fatality rate among persons with 
reported cases of acute hepatitis B is 0.5%–1.0%, with the 
highest rates in adults aged >60 years; however, because a sub­
stantial number of infections are asymptomatic and therefore 
are not reported, the overall fatality rate among all persons 
with HBV infection likely is lower (16). 
Approximately 95% of primary infections in adults with nor­
mal immune status are self-limited, with elimination of virus 
from blood and subsequent lasting immunity to reinfection. 
Chronic infection occurs in <5% of infected persons aged >5 
years, approximately 30% of infected children aged <5 years, 
and approximately 90% of infected infants, with continuing 
viral replication in the liver and persistent viremia (14,17–19). 
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Primary infections become chronic more frequently in immu­
nosuppressed persons (e.g., hemodialysis patients and persons 
with HIV infection) (19,20) and persons with diabetes (21). 
Overall, approximately 25% of persons who become chroni­
cally infected during childhood and 15% of those who become 
chronically infected after childhood die prematurely from cir­
rhosis or liver cancer; the majority remain asymptomatic until 
onset of cirrhosis or end-stage liver disease (22). 
No specific treatment exists for acute hepatitis B; supportive 
care is the mainstay of therapy. Persons who have chronic HBV 
infection require medical evaluation and regular monitoring 
(23–25). Therapeutic agents approved by the Food and Drug 
Administration (FDA) for treatment of chronic hepatitis B can 
achieve sustained suppression of HBV replication and remis­
sion of liver disease in certain persons (24). Periodic screening 
with ultrasonography and alfa-fetoprotein has been demon­
strated to enhance early detection of hepatocellular carcinoma 
(HCC) (25). Certain chronically infected persons with HCC 
have experienced long-term survival after resection of small 
hepatocellular carcinomas, and persons who were screened had 
HCC detected at an earlier stage and had a substantial survival 
advantage compared with historical controls (25); however, data 
from controlled studies are lacking. Guidance for the diagnosis 
and management of hepatitis B is available (26). 
Interpretation of Serologic Markers 
of HBV Infection 
Antigens and antibodies associated with HBV infection in­
clude HBsAg and antibody to HBsAg (anti-HBs), hepatitis B 
core antigen (HBcAg) and antibody to HBcAg (anti-HBc), 
and hepatitis B e antigen (HBeAg) and antibody to HBeAg 
(anti-HBe). At least one serologic marker is present during 
each of the different phases of HBV infection (13,27). The 
serologic markers typically used to differentiate between acute, 
resolving, and chronic infection are HBsAg, anti-HBc, and 
anti-HBs (Table 1). HBeAg and anti-HBe screening typically 
is used for the management of patients with chronic infec­
tion. Serologic assays are available commercially for all mark­
ers except HBcAg because no free HBcAg circulates in blood. 
The presence of a confirmed HBsAg-positive result in 
serum indicates active HBV infection. All HBsAg-positive per­
sons should be considered infectious. In newly infected per­
sons, HBsAg is the only serologic marker detected during the 
first 3–5 weeks after infection. The average time from expo­
sure to detection of HBsAg is 30 days (range: 6–60 days) 
(12,13). Highly sensitive single-sample nucleic acid tests can 
detect HBV DNA in the serum of an infected person 10–20 
days before detection of HBsAg (28). Transient HBsAg posi­
tivity has been reported for up to 18 days after hepatitis B 
vaccination and is clinically insignificant (29,30). 




HBsAg* anti-HBc† anti-HBc Anti-HBs¶ Interpretation
 
–** – – – Never infected 
+††§§ – – – Early acute infection; transient (up to 18 days) after vaccination 
+ + +  – Acute infection 
– + + + or – Acute resolving infection 
– + – + Recovered from past infection and immune 
+ + – – Chronic infection 
– + – – False-positive (i.e., susceptible); past infection; “low-level”
 
chronic infection;¶¶ or passive transfer of anti-HBc to infant
 
born to HBsAg-positive mother
 
– – – + Immune if concentration is >10 mIU/mL after vaccine series
 




* Hepatitis B surface antigen.




¶ Antibody to HBsAg.
 
** Negative test result.
†† Positive test result. 
§§ To ensure that an HBsAg-positive test result is not a false-positive, samples with reactive HBsAg results should be tested with a licensed neutralizing 
confirmatory test if recommended in the manufacturer’s package insert.
¶¶ Persons positive only for anti-HBc are unlikely to be infectious except under unusual circumstances in which they are the source for direct percutane­
ous exposure of susceptible recipients to large quantities of virus (e.g., blood transfusion or organ transplant). 
*** Milli-international units per milliliter. 
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Anti-HBc appears at the onset of symptoms or liver-test 
abnormalities in acute HBV infection and persists for life. 
Acute or recently acquired infection can be distinguished by 
the presence of the immunoglobulin M (IgM) class of anti-
HBc, which is detected at the onset of acute hepatitis B and 
persists for up to 6 months if the disease resolves. In patients 
who have chronic HBV infection, IgM anti-HBc can persist 
during viral replication at low levels that typically are not 
detectable by assays used in the United States. However, per­
sons with exacerbations of chronic infection can test positive 
for IgM anti-HBc (31). Using IgM anti-HBc testing for diag­
nosis of acute hepatitis B should be limited to persons for 
whom clinical evidence of acute hepatitis or an epidemiologic 
link to a case has been identified because the positive predic­
tive value of this test is low in asymptomatic persons. 
In persons who recover from HBV infection, HBsAg is elimi­
nated from the blood, and anti-HBs develops, typically within 
3–4 months. The presence of anti-HBs typically indicates 
immunity from HBV infection. Infection or immunization with 
one serotype of HBV confers immunity to all serotypes. In 
addition, anti-HBs can be detected for several months after hepa­
titis B immune globulin (HBIG) administration. Persons who 
recover from natural infection typically will be positive for both 
anti-HBs and anti-HBc, whereas persons who respond to hepa­
titis B vaccine have only anti-HBs. In persons who become 
chronically infected, HBsAg and anti-HBc persist, typically for 
life. HBsAg will become undetectable in approximately 0.5%– 
2% of persons with chronic infection yearly; anti-HBs will 
occur in the majority of these persons (32–35). 
In certain persons, the only HBV serologic marker detected 
in serum is anti-HBc. Isolated anti-HBc can be detected after 
HBV infection in persons who have recovered but whose anti-
HBs levels have waned. Certain chronically infected persons 
with anti-HBc alone have circulating HBsAg not detectable 
by commercial serology. HBV DNA has been detected in the 
blood of <10% of persons with isolated anti-HBc (36,37). 
These persons are unlikely to be infectious except under cir­
cumstances in which they are a source for direct percutaneous 
exposure of susceptible recipients to substantial quantities of 
virus (e.g., through blood transfusion or organ transplanta­
tion) (38). An isolated anti-HBc result also can be a false-
positive. Typically, the frequency of isolated anti-HBc relates 
directly to the prevalence of HBV infection in the popula­
tion. In populations with a high prevalence of HBV infec­
tion, isolated anti-HBc likely indicates previous infection, with 
loss of anti-HBs. For persons in populations with a low preva­
lence of HBV infection, isolated anti-HBc is found in 
approximately 10%–20% of persons with serologic markers 
of HBV infection (37) and often represents a false-positive 
reaction; the majority of these persons have a primary anti-
HBs response after a 3-dose series of hepatitis B vaccine 
(39,40). 
HBeAg can be detected in the serum of persons with acute 
or chronic HBV infection. The presence of HBeAg correlates 
with high levels of viral replication (i.e., HBV DNA levels 
typically of 107–109 IU/mL, indicating high infectivity) 
(41,42). Loss of HBeAg correlates with low levels (i.e., HBV 
DNA levels of <105 IU/mL) of replicating virus, although 
certain HBeAg-negative persons have HBV DNA levels up to 
108–109 IU/mL (43). A mutation in the precore region of 
the HBV genome has been identified in HBeAg-negative per­
sons with high HBV DNA levels (44,45). 
Epidemiology of HBV Infection 
HBV is transmitted by percutaneous or mucosal exposure 
to infectious blood or body fluids. Although HBsAg has been 
detected in multiple body fluids, only serum, semen, and 
saliva have been demonstrated to be infectious (46,47). HBV 
is concentrated most highly in serum, with lower concentra­
tions in semen and saliva. All HBsAg-positive persons are 
infectious, but those who are also HBeAg positive are more 
infectious because their blood contains high titers of HBV 
(typically HBV DNA levels of 107–109 IU/mL) (41,42). HBV 
is comparatively stable in the environment and remains viable 
for >7 days on environmental surfaces at room temperature 
(48). HBV DNA at concentrations of 102–103 IU/mL can 
be present on environmental surfaces in the absence of any 
visible blood and still cause transmission (48,49). 
For adults, the two primary sources of HBV infection are 
sexual contact and percutaneous exposure to blood. Person-
to-person transmission of HBV also can occur in settings 
involving nonsexual interpersonal contact over an extended 
period (e.g., among household contacts of a person with 
chronic HBV infection and developmentally disabled persons 
living in a long-term–care facility). 
HBV is transmitted efficiently by sexual contact among 
heterosexuals and among MSM. Risk factors associated with 
sexual transmission among heterosexuals include having 
unprotected sex with an infected partner, having unprotected 
sex with more than one partner, and history of another STD. 
Risk factors associated with sexual transmission among MSM 
include having multiple sex partners, history of another STD, 
and anal intercourse. 
Percutaneous transmission of HBV can occur from receipt 
of blood transfusion or organ or tissue transplant from an 
infectious donor; injection-drug use, including sharing of 
injection-preparation equipment; and frequent exposure to 
blood or needles among health-care workers. In the United 
States, donor selection procedures and routine testing of 
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donors have made transmission of HBV via transfusion of 
whole blood and blood components a rare occurrence (50,51). 
Persons with hemophilia who received plasma-derived clot­
ting factor concentrates were previously at high risk for HBV 
infection, but such transmission has been eliminated through 
viral inactivation procedures and use of recombinant clotting 
factor concentrates. Among persons with bleeding disorders 
treated at U.S. hemophilia treatment centers during 1998– 
2002, no infections with viral hepatitis, including HBV, were 
attributable to blood products received during that time (52). 
Outbreaks of HBV infection from exposure to contaminated 
equipment used for therapeutic injections and other health­
care–related procedures, tattooing, and acupuncture also have 
been reported, although such exposures among patients with 
acute hepatitis B are reported rarely (53–57). In the majority 
of cases, transmission resulted from noncompliance with 
aseptic techniques for administering injections and recom­
mended infection-control practices designed to prevent 
cross-contamination of medical equipment and devices. No 
infections have been demonstrated in susceptible persons who 
had oral mucous membrane exposure to HBsAg-positive saliva, 
but transmission has occurred through a human bite and has 
been demonstrated in animals by subcutaneous inoculation 
of saliva (46,58–60). 
Persons living with chronically infected persons are at risk 
for HBV infection through percutaneous or mucosal expo­
sures to blood or infectious body fluids (e.g., sharing a tooth­
brush or razor, contact with exudates from dermatologic 
lesions, or contact with HBsAg-contaminated surfaces). Per­
sons with chronic HBV infection also can transmit HBV in 
other settings (e.g., schools, child care centers, or facilities for 
developmentally disabled persons), especially if they behave 
aggressively or have medical problems (e.g., exudative derma­
titis or open skin lesions) that increase the risk for exposure to 
blood or serous secretions. 
Adults at Risk for HBV Infection 
In the United States in 2005, the highest incidence of acute 
hepatitis B was among adults aged 25–45 years (Figure 1). 
Approximately 79% of newly acquired cases of hepatitis B are 
associated with high-risk sexual activity or injection-drug use; 
other known exposures (i.e., occupational, household, travel, 
and health-care–related) together account for 5% of new cases, 
and 16% deny a specific risk factor for infection (61; CDC, 
unpublished data, 2001–2005). 
Adults at risk for infection by sexual exposure. The most 
common source of HBV infection among adults in the United 
States is sexual contact. Heterosexual transmission accounts 
for approximately 39% of new HBV infections among adults, 
FIGURE 1. Reported incidence* of acute hepatitis B, by age 
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* Per 100,000 population. 
and transmission among MSM accounts for approximately 
24% (CDC, unpublishe data, 2001–2005). Serologic evidence 
of HBV infection (i.e., anti-HBc positive) has ranged from 
10% to 40% among adults seeking treatment in STD clinics 
(62–64) and from 10% to 25% among MSM aged <30 years 
(65; CDC, unpublished data, 1999–2000). Follow-up stud­
ies identified HBV infection in 20%–42% of susceptible het­
erosexual partners of persons with acute hepatitis B (66–68). 
Among susceptible heterosexual spouses of persons with 
chronic HBV infection, the seroprevalence of HBV infection 
ranged from 25% to 59% (69–71). 
Injection-drug users. IDUs account for approximately 16% 
of new HBV infections in the United States (CDC, unpub­
lished data, 2001–2005). Incidence of HBV infection among 
unvaccinated IDUs is high, ranging from 10 to 31 per 100 
person-years (72–74). Risk for HBV transmission increases 
with the number of years of drug use and is associated with 
frequency of injection and with sharing of drug-preparation 
equipment (e.g., cottons, cookers, and rinse water), indepen­
dent of syringe sharing (73,75). 
In a study of the seroprevalence of HBV infection among 
IDUs admitted to drug treatment in six U.S. cities, 64% 
(range: 50%–81%) had serologic evidence of HBV infection, 
and seroprevalence increased with age (76). Studies of 
street-recruited IDUs (77,78) and female IDUs (79) have iden­
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tified similar prevalence of HBV infection, whereas a lower 
prevalence (25%) was found in a study of young IDUs (aged 
18–30 years) (74). Chronic HBV infection has been identi­
fied in 3.1% of IDUs in a detention setting (77) and 7.1% of 
IDUs with HIV coinfection (80). 
Household contacts of persons with chronic HBV infec­
tion. Seroprevalence of HBV infection among susceptible 
household contacts of persons with chronic infection has var­
ied, ranging from 14% to 60% (69,71,81–85). The risk for 
infection is highest among sex partners of, and children living 
with, a person with chronic HBV infection in a household or 
extended family setting (83–85). 
Developmentally disabled persons in long-term–care 
facilities. Developmentally disabled persons in residential and 
nonresidential facilities historically have had high rates of HBV 
infection (86,87), but the prevalence of infection has declined 
substantially since the implementation of routine hepatitis B 
vaccination in these settings (88,89). Nonetheless, because 
HBsAg-positive persons reside in such facilities, clients and 
staff continue to be at risk for infection. 
Persons at risk for occupational exposure to HBV. 
Before hepatitis B vaccination was widely implemented, HBV 
infection was recognized as a common occupational hazard 
among persons who were exposed to blood while caring for 
patients or working in laboratories (90,91). Since then, rou­
tine hepatitis B vaccination of health-care workers and use of 
standard precautions to prevent exposure to bloodborne patho­
gens have made HBV infection a rare event in these popula­
tions (92–94). Since the mid-1990s, the incidence of HBV 
infection among health-care workers has been lower than that 
among the general population (94). Public safety workers with 
exposures to blood also might be at risk for HBV infection 
(95–97); however, the prevalence of HBV infection in occu­
pational groups such as police officers, firefighters, and cor­
rections officers generally does not differ from that in the 
general population when adjusted for race and age (97), and 
infection is associated most often with nonoccupational risk 
factors (97,98). No increased risk for occupationally acquired 
HBV infection has been documented in workers exposed 
infrequently to blood or body fluids (e.g., ward clerks, dietary 
workers, maintenance workers, housekeeping personnel, teach­
ers, and persons employed in day care settings) (91). 
Hemodialysis patients. Since the initiation of strict infec­
tion-control practices and hepatitis B vaccination, the rate of 
HBV infection among patients undergoing hemodialysis has 
declined approximately 95% (99,100). Nonetheless, repeated 
outbreaks of HBV infection among unvaccinated patients 
underscore the continued risk for infection in this population (101). 
Persons with chronic liver disease. Persons with chronic 
liver disease are not at increased risk for HBV infection unless 
they have percutaneous or mucosal exposure to infectious 
blood or body fluids. Furthermore, studies of the outcomes 
of acute hepatitis B among patients with chronic liver disease 
provide little evidence that acute hepatitis B increases their 
risk for an acute liver failure. However, concurrent chronic 
HBV infection might increase the risk for progressive chronic 
liver disease in HCV-infected patients (102). 
Travelers to HBV-endemic regions. Short-term travelers 
to regions in which HBV infection is of high or intermediate 
endemicity (Box 2) typically are at risk for infection only 
through exposure to blood in medical, health-care, or disaster-
relief activities; receipt of medical care that involves parenteral 
exposures; or sexual activity or drug use (103). Infection rates 
of 2%–5% per year among persons working in such regions 
for >6 months have been reported (104,105). 
HIV-positive persons. Published data on the overall preva­
lence of HBV and HIV coinfection in the United States are 
BOX 2. Geographic regions* with intermediate† and high§ 
hepatitis B virus endemicity 
Africa: all countries 
East Asia: all countries 
Eastern Europe and Northern Asia: all countries 
except Hungary 
South Asia: all countries except Sri Lanka 
Southeast Asia: all countries 
Australia and the South Pacific: all countries and 
territories except Australia and New Zealand 
Middle East: all countries except Cyprus 
Western Europe: Greece, Malta, Portugal, and Spain 
and indigenous populations of Greenland 
North America: Alaska Natives and indigenous 
populations of Northern Canada 
Central America: Belize, Guatemala, Honduras, and 
Panama 
South America: Argentina, Bolivia, Brazil, Ecuador, Guyana, 
Suriname, Venezuela, and the Amazonian areas of 
Colombia and Peru 
Caribbean: Antigua and Barbuda, Dominica, 
Dominican Republic, Grenada, Haiti, Jamaica, Puerto 
Rico, St. Kitts and Nevis, St. Lucia, St. Vincent and 
Grenadines, Trinidad and Tobago, and Turcs and 
Caicos 
* A complete list of countries in each region is available at http://www.cdc. 
gov/travel/destinat.htm. 
† Hepatitis B surface antigen (HBsAg) prevalence of 2%–7%. 
§ HBsAg prevalence of >8%. 
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limited. Studies of certain subgroups have identified prevalence 
of previous or current HBV infection of 45% in HIV-infected 
MSM aged 22–29 years (CDC, unpublished data, 1998–2000), 
24% in adolescent HIV-infected males (106), and 43% in HIV-
infected women, including 76% among HIV-infected female 
IDUs (79). Chronic HBV infection has been identified in 
6%–14% of HIV-positive persons from Western Europe and 
the United States, including 9%–17% of MSM, 7%–10% of 
IDUs, and 4%–6% of heterosexuals (107). 
The course of HBV infection can be modified in the pres­
ence of HIV, with a lower incidence of jaundice and a higher 
incidence of chronic HBV infection (20,108,109). Limited 
data also indicate that HIV-infected patients with chronic HBV 
infection have an increased risk for liver-related mortality and 
morbidity (110). 
Incidence of Acute Hepatitis B 
During 1990–2005, the overall incidence of reported acute 
hepatitis B declined 78%, from 8.5 to 1.9 per 100,000 popu­
lation (Figure 2), and the estimated number of new HBV 
infections, after adjusting for underreporting and asymptom­
atic infections, declined from approximately 232,000 to 
approximately 51,000 infections (CDC, unpublished data, 
1990–2005). Among children and adolescents aged <19 years, 
incidence declined 96%, from 2.4 to 0.1 per 100,000 popu­
lation. Among adults aged >19 years, incidence declined 76%, 
from 9.9 to 2.4 per 100,000 population, and racial/ethnic 
disparities in incidence were nearly eliminated for Asians/ 
Pacific Islanders, American Indians/Alaska Natives, and His­
panics (Figure 3). Incidence also declined substantially among 
blacks aged >19 years during this period, from 19.7 to 4.2 per 
100,000 population; however, in 2005, incidence among 
blacks remained nearly three times higher than that among 
other racial/ethnic populations. After leveling during 1999– 
FIGURE 2. Reported incidence* of acute hepatitis B, by age 













1990 1995 2000 2005 
Year 
* Per 100,000 population. 
FIGURE 3. Reported incidence* of acute hepatitis B among 
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2002, acute hepatitis B incidence among adults decreased 35% 
during 2002–2005, from 3.7 to 2.4 per 100,000 population 
(CDC, unpublished data, 2006). In 2005, the highest inci­
dence of acute hepatitis B occurred among persons aged 
25–44 years. 
Prevalence of HBV Infection 
During 1988–1994, the overall age-adjusted prevalence of 
HBV infection (including previous or chronic infection) in 
the U.S. population was 4.9%, and the prevalence of chronic 
infection was 0.4% (111). Persons who have immigrated to 
the United States from countries in which HBV is endemic 
(Box 2, Figure 4) are affected disproportionately by chronic 
HBV infection; in particular, the majority of chronic HBV 
infections in the United States are among Asians/Pacific 
Islanders (112–114). The prevalence of chronic HBV infec­
tion among persons immigrating to the United States from 
Central and Southeast Asia, the Middle East, and Africa var­
ies (range: 5%–15%) and reflects the patterns of HBV infec­
tion in the countries and regions of origin. During 1994–2003, 
approximately 40,000 immigrants with chronic HBV infec­
tion were admitted annually to the United States for perma­
nent residence (115; CDC, unpublished data, 2005). 
Prophylaxis Against HBV Infection 
Hepatitis B Vaccine 
Hepatitis B vaccine is available as a single-antigen formula­
tion and also in fixed combination with other vaccines. Two 
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FIGURE 4. Geographic distribution of chronic hepatitis B virus (HBV) infection — worldwide, 2005* 
HBsAg prevalence 
>8% = high 
2%–7% = intermediate 
<2% = low 
* For multiple countries, estimates of prevalence of hepatitis B surface antigen (HBsAg), a marker of chronic HBV infection, are based on limited data and 
might not reflect current prevalence in countries that have implemented childhood hepatitis B vaccination. In addition, HBsAg prevalence might vary 
within countries by subpopulation and locality. 
single-antigen vaccines are available in the United States: 
Recombivax HB® (Merck & Co., Inc., Whitehouse Station, 
New Jersey) and Engerix-B® (GlaxoSmithKline Biologicals, 
Rixensart, Belgium). Of the three licensed combination vac­
cines, one (Twinrix® [GlaxoSmithKline Biologicals, Rixensart, 
Belgium]) is used for vaccination of adults and two (Comvax® 
[Merck & Co., Inc., Whitehouse Station, New Jersey] and 
Pediarix® [GlaxoSmithKline Biologicals, Rixensart, Belgium]) 
are used for vaccination of infants and young children. Twinrix 
contains recombinant HBsAg and inactivated hepatitis A virus. 
Comvax contains recombinant HBsAg and Haemophilus 
influenzae type b (Hib) polyribosylribitol phosphate conju­
gated to Neisseria meningitidis outer membrane protein com­
plex. Pediarix contains recombinant HBsAg, diphtheria and 
tetanus toxoids and acellular pertussis adsorbed (DTaP), and 
inactivated poliovirus (IPV). 
HBsAg is the antigen used for hepatitis B vaccination 
(116,117). Vaccine antigen can be purified from the plasma 
of persons with chronic HBV infection or produced by 
recombinant DNA technology. For vaccines available in the 
United States, recombinant DNA technology is used to 
express HBsAg in yeast, which then is purified from the cells 
by biochemical and biophysical separation techniques 
(118,119). Hepatitis B vaccines licensed in the United States 
are formulated to contain 10–40 µg of HBsAg protein/mL. 
Hepatitis B vaccines produced for distribution in the United 
States do not contain thimerosal as a preservative or contain 
only a trace amount (<1.0 µg mercury/mL) from the manu­
facturing process (120,121). 
Hepatitis B Immune Globulin 
HBIG provides passively acquired anti-HBs and temporary 
protection (i.e., 3–6 months) when administered in standard 
doses. HBIG typically is used as an adjunct to hepatitis B 
vaccine for postexposure immunoprophylaxis to prevent HBV 
infection. For nonresponders to hepatitis B vaccination, HBIG 
administered alone is the primary means of protection after 
an HBV exposure. 
HBIG is prepared from the plasma of donors with high 
concentrations of anti-HBs. The plasma is screened to elimi­
nate donors who are positive for HBsAg, antibodies to HIV 
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and hepatitis C virus (HCV), and HCV RNA. In addition, 
proper manufacturing techniques for HBIG inactivate viruses 
(e.g., HBV, HCV, and HIV) from the final product (122,123). 
No evidence exists to indicate that HBV, HCV, or HIV ever 
has been transmitted by HBIG commercially available in the 
United States. HBIG that is commercially available in the 
United States does not contain thimerosal. 
Adult Vaccination Schedules 
and Results of Vaccination 
Preexposure Vaccination 
Vaccination of Adults 
Primary vaccination consists of >3 intramuscular doses of 
hepatitis B vaccine (Table 2). The 3-dose vaccine series 
administered intramuscularly at 0, 1, and 6 months produces 
a protective antibody response in approximately 30%–55% 
of healthy adults aged <40 years after the first dose, 75% after 
the second dose, and >90% after the third dose (124,125). 
After age 40 years, the proportion of persons who have a pro­
tective antibody response after a 3-dose vaccination regimen 
declines below 90%, and by age 60 years, protective levels of 
antibody develop in only 75% of vaccinated persons (126). 
In addition to age, other host factors (e.g., smoking, obesity, 
genetic factors, and immune suppression) contribute to 
decreased vaccine response (127–130). Alternative vaccina­
tion schedules (e.g., 0, 1, and 4 months or 0, 2, and 4 months) 
have been demonstrated to elicit dose-specific and final rates 
of seroprotection similar to those obtained on a 0-, 1-, 
6-month schedule (131). 
The combined hepatitis A–hepatitis B vaccine (Twinrix) is 
indicated for vaccination of persons aged >18 years with risk 
factors for both hepatitis A and hepatitis B. The dosage of the 
hepatitis A component in the combined vaccine is lower than 
that in the single-antigen hepatitis A vaccine, allowing it to be 
administered in a 3-dose schedule instead of the 2-dose sched­
ule used for the single-antigen vaccine. 
Nonstandard Vaccine Schedules 
No apparent effect on immunogenicity has been docu­
mented when minimum spacing of doses (i.e., 4 weeks 
between doses 1 and 2, 8 weeks between doses 2 and 3, and 
16 weeks between doses 1 and 3) is not achieved precisely. 
Increasing the interval between the first 2 doses has little 
effect on immunogenicity or final antibody concentration 
(132–134). The third dose confers the maximum level of 
seroprotection but acts primarily as a booster and appears to 
provide optimal long-term protection (135). Longer intervals 
between the last 2 doses result in higher final antibody levels 
but might increase the risk for acquisition of HBV infection 
among persons who have a delayed response to vaccination. 
No differences in immunogenicity are observed when vac­
cines from different manufacturers are used to complete the 
vaccine series. 
Response to Revaccination 
Although serologic testing for immunity is not necessary 
after routine vaccination of adults, postvaccination testing is 
recommended for persons whose subsequent clinical manage­
ment depends on knowledge of their immune status, includ­
ing certain health-care and public safety workers; chronic 
hemodialysis patients, HIV-infected persons, and other 
immunocompromised persons; and sex or needle-sharing part­
ners of HBsAg-positive persons (Appendix A). Of persons who 
did not respond to a primary 3-dose vaccine series with anti-
HBs concentrations of >10 mIU/mL, 25%–50% responded 
to an additional vaccine dose, and 44%–100% responded to 
a 3-dose revaccination series (136–141). Better response to 
TABLE 2. Recommended doses of currently licensed formulations of adult hepatitis B vaccine, by group and vaccine type 
Single-antigen vaccine Combination vaccine 
Recombivax HB®* Engerix-B®† 
Dose Vol. Dose Vol. 
Twinrix®†§ 
Dose Vol. 
Group (µg)¶ (mL) (µg)¶ (mL) (µg)¶ (mL) 
Adults (aged >20 years) 
Hemodialysis patients and other immunocompromised 













* Merck & Co., Inc., Whitehouse Station, New Jersey.
† GlaxoSmithKline Biologicals, Rixensart, Belgium.
§ Combined hepatitis A and hepatitis B vaccine, recommended for persons aged >18 years who are at increased risk for both hepatitis B virus and 
hepatitis A virus infections.
¶ Recombinant hepatitis B surface antigen protein dose. 
** Dialysis formulation administered on a 3-dose schedule at 0, 1, and 6 months.
†† Two 1.0-mL doses administered in 1 or 2 injections on a 4-dose schedule at 0, 1, 2, and 6 months.
§§ Not applicable. 
11 Vol. 55 / RR-16 Recommendations and Reports 
revaccination occurs in persons who have measurable but low 
(<10 mIU/mL) levels of antibody after the initial series 
(136,137). Increased vaccine doses (e.g., double the standard 
dose) were demonstrated to enhance revaccination response 
rates in one study (140) but not in another (138). Intrader­
mal vaccination has been reported to be immunogenic in per­
sons who did not respond to intramuscular vaccination 
(142,143); however, intradermal vaccination is not a route of 
administration indicated in the manufacturers’ package label­
ing. Persons who do not have protective levels of anti-HBs 
1–2 months after revaccination either are primary 
nonresponders or are infected with HBV. Genetic factors might 
contribute to nonresponse to hepatitis B vaccination 
(130,137). 
Groups Requiring Different Vaccination Doses 
or Schedules 
Compared with immunocompetent adults, hemodialysis 
patients are less likely to have protective levels of antibody 
after vaccination with standard vaccine dosages; protective 
levels of antibody developed in 67%–86% (median: 64%) of 
adult hemodialysis patients who received 3–4 doses of either 
vaccine in various dosages and schedules (100). Higher 
seroprotection rates have been identified in patients with 
chronic renal failure, particularly those with mild or moder­
ate renal failure, who were vaccinated before becoming dialy­
sis dependent. After vaccination with a 4-dose series, the 
seroprotection rate among adult predialysis patients with 
serum creatinine levels of <4.0 mg/dL was 86%, compared 
with 37% among patients with serum creatinine levels of >4.0 
mg/dL, 88% of whom were dialysis patients (144). 
Humoral response to hepatitis B vaccination also is reduced 
in other immunocompromised persons (e.g., HIV-infected 
persons, hematopoietic stem-cell transplant recipients, and 
patients undergoing chemotherapy) (145–147). Modified 
dosing regimens, including doubling the standard antigen dose 
or administering additional doses, might increase response rates 
(148–150). However, limited data regarding response to these 
alternative vaccination schedules are available. 
Immune Memory 
Anti-HBs is the only easily measurable correlate of vaccine-
induced protection. Immunocompetent persons who achieve 
anti-HBs concentrations of >10 mIU/mL after preexposure 
vaccination have nearly complete protection against both acute 
disease and chronic infection, even if anti-HBs concentrations 
decline subsequently to <10 mIU/mL (151–154). Although 
immunogenicity is lower among immunocompromised per­
sons, those who achieve and maintain a protective antibody 
response before exposure to HBV have a high level of protec­
tion from infection (155,156). 
After primary immunization with hepatitis B vaccine, anti-
HBs levels decline rapidly within the first year and more slowly 
thereafter. Among young adults who respond to a primary 
vaccine series with antibody concentrations of >10 mIU/mL, 
17%–50% have low or undetectable concentrations of anti-
HBs (reflecting anti-HBs loss) 10–15 years after vaccination 
(155–157). In the absence of exposure to HBV, the persis­
tence of detectable anti-HBs after vaccination depends on the 
concentration of postvaccination antibodies (158). 
Even when anti-HBs concentrations decline to <10 mIU/mL, 
nearly all vaccinated persons remain protected against HBV 
infection. The mechanism for continued vaccine-induced pro­
tection is thought to be the preservation of immune memory 
through selective expansion and differentiation of clones of 
antigen-specific B and T lymphocytes (159). Persistence of 
vaccine-induced immune memory among persons who 
responded to a primary adult vaccine series 4–23 years previ­
ously but then had anti-HBs concentrations of <10 mIU/mL 
has been demonstrated by an anamnestic increase in anti-HBs 
concentrations in 74%–100% of these persons 2–4 weeks 
after administration of an additional vaccine dose and by 
antigen-specific B and T cell proliferation (160). Although 
direct measurement of immune memory is not yet possible, 
these data indicate that a high proportion of vaccinees retain 
immune memory and would have an anti-HBs response upon 
exposure to HBV. 
Population-based studies of highly vaccinated populations 
have demonstrated elimination of new HBV infections for up 
to 2 decades after hepatitis B immunization programs were 
initiated (161–163). Breakthrough infections (detected by the 
presence of anti-HBc or HBV DNA) have been documented 
in a limited percentage of vaccinated persons (159,164), but 
these infections typically are transient and asymptomatic; 
breakthrough infections resulting in chronic HBV infection 
have been documented only rarely among infants born to 
HBsAg-positive mothers (165) and have not been observed 
among immunocompetent adults. 
Limited data are available on the duration of immune 
memory after hepatitis B vaccination in immunocompromised 
persons (e.g., HIV-infected patients, dialysis patients, patients 
undergoing chemotherapy, or hematopoietic stem-cell trans­
plant patients). No clinically significant HBV infections have 
been documented among immunocompromised persons who 
maintain protective levels of anti-HBs. In studies of long-term 
protection among HIV-infected persons, breakthrough infec­
tions occurring after a decline in anti-HBs concentrations to 
<10 mIU/mL have been transient and asymptomatic (155). 
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However, among hemodialysis patients who responded to the 
vaccine, clinically significant HBV infection has been docu­
mented in persons who have not maintained anti-HBs con­
centrations of >10 mIU/mL (166). 
Postexposure Prophylaxis 
Both passive-active postexposure prophylaxis (PEP) using 
HBIG and hepatitis B vaccine and active PEP using hepatitis 
B vaccine alone are highly effective in preventing infection 
after exposure to HBV (167–170). HBIG alone has also been 
demonstrated to be effective in preventing HBV transmission 
(68,171–173), but with the availability of hepatitis B vac­
cine, HBIG typically is used as an adjunct to vaccination. 
Guidelines for PEP for adults with occupational (174) and 
nonoccupational exposures (Appendix B) to HBV have been 
developed. 
The major determinant of the effectiveness of PEP is early 
administration of the initial dose of vaccine. The effectiveness 
of PEP diminishes the longer after exposure it is initiated 
(27,175,176). Studies are limited on the maximum interval 
after exposure during which PEP is effective, but the interval 
is likely <7 days for needlestick (171,172,177) exposures and 
<14 days for sexual exposures (68,154,168,170,173). 
Substantial evidence suggests that adults who respond to 
hepatitis B vaccination are protected from chronic HBV 
infection for at least 20 years even if vaccinees lack detectable 
anti-HBs at the time of an exposure (151–153). For this rea­
son, immunocompetent persons who have had postvaccina­
tion testing and are known to have responded to hepatitis B 
vaccination with anti-HBs concentrations of >10 mIU/mL 
do not require additional passive or active immunization after 
an HBV exposure and do not need further periodic testing to 
assess anti-HBs concentrations. 
Vaccine Safety 
Hepatitis B vaccines have been demonstrated to be safe when 
administered to infants, children, adolescents, and adults 
(178). Since 1982, an estimated 70 million adolescents and 
adults and 50 million infants and children in the United States 
have received >1 dose of hepatitis B vaccine (CDC, unpub­
lished data, 2004). 
Vaccine Reactogenicity 
The most frequently reported side effects in persons receiv­
ing hepatitis B vaccine are pain at the injection site (3%–29%) 
and temperature of >99.9 °F (>37.7°C) (1%–6%) (124,125). 
However, in placebo-controlled studies, these side effects were 
reported no more frequently among persons receiving hepati­
tis B vaccine than among persons receiving placebo (179). 
Adverse Events 
CDC and FDA continually assess the safety of hepatitis B 
vaccine and other vaccines through ongoing monitoring of 
data from the Vaccine Safety Datalink (VSD) project, the 
Vaccine Adverse Events Reporting System (VAERS), and other 
surveillance systems. A causal association has been established 
between receipt of hepatitis B vaccine and anaphylaxis (178). 
On the basis of VSD data, the estimated incidence of anaphy­
laxis among children and adolescents who received hepatitis 
B vaccine is one case per 1.1 million vaccine doses distributed 
(95% confidence interval = 0.1–3.9) (180). 
Early postlicensure surveillance of adverse events suggested 
a possible association between Guillain-Barré syndrome (GBS) 
and receipt of the first dose of plasma-derived hepatitis B vac­
cine among U.S. adults (181). However, in a subsequent analy­
sis of GBS cases reported to CDC, FDA, and vaccine 
manufacturers, among an estimated 2.5 million adults who 
received >1 dose of recombinant hepatitis B vaccine during 
1986–1990, the rate of GBS that occurred after hepatitis B 
vaccination did not exceed the background rate among 
unvaccinated persons (CDC, unpublished data, 1992). An 
Institute of Medicine review concluded that evidence was 
insufficient to reject or accept a causal association between 
GBS and hepatitis B vaccination (178,182,183). 
One retrospective case-control study (184,185) reported an 
association between hepatitis B vaccine and multiple sclerosis 
(MS) among adults. However, multiple studies (186–189) have 
demonstrated no such association. Reviews by scientific pan­
els have favored rejection of a causal association between hepa­
titis B vaccination and MS (190,191). 
In rare instances, chronic illnesses have been reported after 
hepatitis B vaccination, including chronic fatigue syndrome 
(192), neurologic disorders (e.g., leukoencephalitis, optic neu­
ritis, and transverse myelitis) (193–195), rheumatoid arthri­
tis (196,197), type 1 diabetes (198), and autoimmune disease 
(199). However, no evidence of a causal association between 
these conditions or other chronic illnesses and hepatitis B vac­
cine has been demonstrated (183,190,200–203). 
Reported episodes of alopecia (hair loss) after rechallenge 
with hepatitis B vaccine suggest that vaccination might, in 
rare cases, trigger episodes of alopecia (204). However, a popu­
lation-based study determined no statistically significant 
association between alopecia and hepatitis B vaccine (205). 
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Contraindications and Precautions 
Hepatitis B vaccination is contraindicated for persons with 
a history of hypersensitivity to yeast or any vaccine compo­
nent (206–209). Despite a theoretic risk for allergic reaction 
to vaccination in persons with allergy to Saccharomyces cerevisiae 
(baker’s yeast), no evidence exists to document adverse reac­
tions after vaccination of persons with a history of yeast allergy. 
Persons with a history of serious adverse events (e.g., anaphy­
laxis) after receipt of hepatitis B vaccine should not receive 
additional doses. As with other vaccines, vaccination of persons 
with moderate or severe acute illness, with or without fever, 
should be deferred until illness resolves (210). Vaccination is 
not contraindicated in persons with a history of MS, GBS, 
autoimmune disease (e.g., systemic lupus erythematosis or rheu­
matoid arthritis), or other chronic diseases. 
Pregnancy is not a contraindication to vaccination. Limited 
data suggest that developing fetuses are not at risk for adverse 
events when hepatitis B vaccine is administered to pregnant 
women (211). Available vaccines contain noninfectious HBsAg 
and should cause no risk of infection to the fetus. 
Implementation Barriers 
and Rationale for New 
Recommendations 
Soon after hepatitis B vaccine was licensed in 1982, ACIP 
recommended vaccination for adults at increased risk for HBV 
infection (212). However, the recommendations were not 
widely implemented, and coverage among adults at risk for 
HBV infection remained low. By the early 1990s, the diffi­
culty in vaccinating adults at risk for HBV infection and the 
substantial burden of HBV-related disease resulting from 
infections acquired during childhood indicated that additional 
hepatitis B vaccination strategies were needed (213,214). In 
1991, recommendations for vaccination of unvaccinated adults 
at high risk for HBV infection became part of the national 
strategy adopted by ACIP and professional medical organiza­
tions to eliminate HBV transmission in the United States (3). 
However, hepatitis B vaccine still is not offered routinely in 
medical settings serving adults, and a substantial number of 
adults at risk for HBV infection remain unvaccinated. 
Multiple factors contribute to low hepatitis B vaccination 
coverage among adults at risk. In contrast to vaccination of 
children, no national program exists to support vaccine pur­
chase and infrastructure for vaccine delivery to uninsured and 
underinsured adults. Reimbursement mechanisms for vacci­
nation of adults with health insurance also are not widely used. 
In addition, certain patients and health-care providers are 
reluctant to discuss risk behaviors (215), and providers might 
not make hepatitis B vaccination a priority compared with 
other clinical care services. 
One strategy demonstrated to be effective at increasing vac­
cination coverage among adults at risk for HBV infection is 
to offer vaccination to all adults as part of routine prevention 
services in settings in which a high proportion of adults have 
HBV risk factors (10,216–223). In STD and HIV treatment 
facilities, health-care settings serving IDUs, and health-care 
settings targeting services to MSM, nearly all patients have 
behavioral risk factors for HBV infection. Furthermore, a high 
proportion of persons receiving health care in HIV testing 
facilities or correctional facilities report sexual and drug-use 
risk behaviors (224,225). Therefore, providing hepatitis B 
vaccination in these settings offers an efficient and effective 
way to reach adults at highest risk. During 2001–2004, in a 
study of 760 adults with reported acute hepatitis B who par­
ticipated in CDC’s Sentinel Counties Study of Viral Hepati­
tis, 39% reported a history of STD treatment, 40% reported 
a history of incarceration, and 22% reported a history of drug 
treatment; overall, 61% would have had at least one opportu­
nity to be vaccinated either during STD or drug treatment or 
at a correctional facility (226). 
Demonstration projects that supported the purchase of hepa­
titis B vaccine and its administration in settings in which a 
high proportion of adults have HBV risk factors have estab­
lished the feasibility of providing the vaccine as part of com­
prehensive STD, HIV, and hepatitis prevention services (10). 
When clients were offered hepatitis B vaccination in such set­
tings, first-dose acceptance rates of 70%–85% were achieved 
(10,216,223,227). These demonstration projects have identi­
fied the components of successful adult hepatitis B vaccina­
tion programs (Box 3). In addition, “one-stop” delivery of 
integrated prevention services was preferred by the majority 
of patients and typically resulted in enhanced delivery of all 
BOX 3. Components of a successful adult hepatitis B vac­
cination program 
• Institutional commitment to the program 
• Trained and knowledgeable staff who promote the pro­
gram 
• Patients who are informed about hepatitis B and the 
health benefits of hepatitis B vaccination 
• Integrated delivery of vaccination and other services 
• Protocols and standing orders 
• Protected patient confidentiality 
• Infrastructure that ensures vaccine administration is 
accessible, convenient, and flexible for patients 
• Funding for vaccine 
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prevention services (227). Return visits for second and third 
doses of hepatitis B vaccine also provide opportunities for 
patients to receive other STD/HIV-related services (e.g., test 
results, additional counseling, and referral). Multiple studies 
have established the cost-effectiveness of providing hepatitis 
B vaccination at STD/HIV counseling and testing sites, cor­
rectional institutions, drug-abuse treatment centers, and other 
settings serving adults at risk for HBV infection (228–231). 
Universal vaccination of adults in settings in which a high 
proportion of persons have HBV risk factors will reach a sub­
stantial proportion of all adults at risk for HBV infection. 
However, not all adults with risk factors for HBV infection 
visit these settings. For example, an estimated 80%–95% of 
STDs are diagnosed in settings other than STD clinics 
(232,233). Therefore, primary care and clinical preventive 
service providers (e.g., physicians’ offices, community health 
centers, family planning clinics, liver disease clinics, and travel 
clinics) also should provide hepatitis B vaccine whenever 
indicated or requested as part of regular preventive care. Lim­
ited data are available regarding best practices in primary care 
and specialty medical settings to achieve high vaccination cov­
erage among adults at risk for HBV infection. In one project 
in which hepatitis B vaccine was made available free of charge 
to primary care clients in community clinics, low vaccination 
coverage rates were observed, compared with rates at other 
venues (10). This finding suggests that provision of free vac­
cine alone might not ensure increased use of hepatitis B vac­
cine and that other implementation strategies (e.g., education 
and training of clinicians and standing orders) are needed to 
prompt providers to offer vaccination to adults. 
In primary care settings, targeting vaccination to persons at 
risk is an efficient approach to preventing HBV infection. 
During 2001–2005, among persons with acute hepatitis B 
who participated in CDC’s Sentinel Counties Study of Viral 
Hepatitis, 84% reported risk behaviors or characteristics, 
either during the incubation period (i.e., 6 weeks–6 months) 
or during their lifetimes, that placed them in a group for which 
hepatitis B vaccination was recommended (CDC, unpublished 
data, 2001–2005). Providers in primary care settings can 
ascertain patients’ risks for HBV infection and identify candi­
dates for hepatitis B vaccination during routine patient visits. 
Assessment of patients’ sex- and drug-related risk factors is 
recommended by the U.S. Preventive Services Task Force and 
the American Medical Association (AMA) (234,235) and has 
the ancillary benefit of identifying candidates for other pre­
vention interventions (e.g., screening for HIV infection and 
other STDs and drug-abuse treatment). 
However, risk-targeted approaches can miss persons in need 
of prevention services. Patients might be reluctant to report sex-
and drug-related behaviors, particularly when these behaviors are 
not perceived as relevant to the clinical encounter. In addition, 
despite recommendations of the U.S. Preventive Services Task 
Force and AMA, providers might be reluctant to inquire about 
behavioral risk factors. For example, surveys of physicians and 
patients conducted during 1995–1999 indicated that fewer than 
half of patients were asked about sexual behaviors (236–238). 
Health-care providers should educate all patients about the 
health benefits of hepatitis B vaccination, including risk factors 
for HBV infection and the importance of vaccination for per­
sons who engage in certain risk behaviors. This information 
might stimulate patients to request vaccination from their pri­
mary care providers, without requiring them to acknowledge a 
specific risk factor. 
Another possible strategy is to offer vaccination to all adults 
in age groups with the highest incidence of infection as part 
of routine medical care (Figure 1). An age-based approach 
might simplify vaccination-related decision-making by prac­
titioners and remove the stigma associated with disclosure of 
risk behaviors. Other adult vaccines, including those for 
influenza and pneumococcal disease, are delivered on age-based 
schedules. However, the effectiveness of age-based strategies 
in increasing hepatitis B vaccination coverage among adults 
at risk is unknown. In addition, age-based strategies for adult 
vaccination would be substantially more costly than risk-
targeted approaches (CDC, unpublished data, 2005). 
Lack of funding for vaccine and its administration is a 
major barrier to provision of hepatitis B vaccine to adults. 
Hepatitis B vaccine often is a reimbursable charge in health-
care settings that bill insurance or Medicaid for services, and 
surveys of public and private insurers indicate high rates of 
coverage for hepatitis B vaccination (239,240). In one study, 
an estimated 74% of adults aged 18–49 years with risk factors 
for HBV infection had health insurance coverage (241). How­
ever, public clinics might not have systems in place to bill for 
vaccination services, and reimbursement of private providers 
might be inadequate to cover the purchase and administra­
tion of vaccine. Other adults either lack private insurance or 
are not eligible for reimbursement by Medicaid. Although the 
Vaccines for Children program provides federally funded vac­
cine and administration costs for vaccination of uninsured 
and underinsured children and youth aged <19 years, no simi­
lar program supports adult vaccination. 
Certain adult hepatitis B vaccination programs have been 
successful at identifying federal, state, or local funds to 
provide free or low-cost hepatitis B vaccination to uninsured 
or underinsured adults. For example, the Immunization Grant 
Program, created under Section 317 of the Public Health 
Service Act, provides funding to state, local, and territorial 
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public health agencies for vaccine purchase and vaccination-
program operation (242). Section 317 funds can be used to 
purchase childhood and adult vaccines, including adult hepa­
titis B vaccine. However, lack of adequate funding constrains 
efforts to increase vaccination coverage among adults. To 
maximize available resources for hepatitis B vaccination, pub­
lic and private health-care providers should become familiar 
with insurance billing and reimbursement mechanisms that 
can be used for hepatitis B vaccine. AMA billing and reim­
bursement guidelines are available at http://www.ama-assn.org/ 
ama1/pub/upload/mm/36/ama_hep_coding_trifo.pdf. 
Although HBV infections are expected to decline as a result 
of universal childhood immunization and increased vaccina­
tion of adults at risk, an estimated 1.25 million persons in the 
United States are living with chronic HBV infection and 
require essential prevention services and medical management. 
In particular, Asians/Pacific Islanders in the United States have 
a high prevalence of chronic HBV infection, representing a 
major health disparity. Persons with chronic HBV infection 
often are unaware of their infection status or do not receive 
needed care. Few programs have been implemented to iden­
tify HBsAg-positive persons, provide or refer these persons 
for appropriate medical management, and provide vaccina­
tion to their contacts (243). During delivery of hepatitis B 
vaccination and provision of other preventive services, health-
care providers have opportunities to identify persons with 
chronic HBV infection, refer them for counseling and man­
agement, and ensure that their susceptible contacts receive 
vaccination. Guidelines to identify and manage HBsAg­
positive persons have been developed (Appendix C). 
Implementation of the recommendations and strategies 
outlined in this report and the companion ACIP recommen­
dations for infants, children, and adolescents (11) should lead 
ultimately to the elimination of HBV transmission in the 
United States. New information will have implications for this 





for Hepatitis B Vaccination of Adults
 
Recommendations 
• Hepatitis B vaccination is recommended for all unvacci­
nated adults at risk for HBV infection and for all adults 
requesting protection from HBV infection (Box 4). 
Acknowledgment of a specific risk factor should not be a 
requirement for vaccination. 
BOX 4. Adults recommended to receive hepatitis B vaccination 
Persons at risk for infection by sexual exposure 
• Sex partners of hepatitis B surface antigen (HBsAg)­
positive persons 
• Sexually active persons who are not in a long-term, 
mutually monogamous relationship (e.g., persons with 
more than one sex partner during the previous 6 months) 
• Persons seeking evaluation or treatment for a sexually 
transmitted disease 
• Men who have sex with men 
Persons at risk for infection by percutaneous or 
mucosal exposure to blood 
• Current or recent injection-drug users 
• Household contacts of HBsAg-positive persons 
• Residents and staff of facilities for developmentally 
disabled persons 
• Health-care and public safety workers with reasonably 
anticipated risk for exposure to blood or blood-
contaminated body fluids 
• Persons with end-stage renal disease, including 
predialysis, hemodialysis, peritoneal dialysis, and home 
dialysis patients 
Others 
• International travelers to regions with high or interme­
diate levels (HBsAg prevalence of >2%) of endemic HBV 
infection (Figure 4, Box 2) 
• Persons with chronic liver disease 
• Persons with HIV infection 
• All other persons seeking protection from HBV infection 
• Providers should select the vaccine schedule they consider 
necessary to achieve completion of the vaccine series 
(Table 2, Box 5). 
• Public health programs and primary care providers should 
adopt strategies appropriate for the practice setting to 
ensure that all adults at risk for HBV infection are offered 
hepatitis B vaccine (Box 6). 
BOX 5. Hepatitis B vaccine schedules for adults (aged >20 
years)* 
0, 1, and 6 months 
0, 1, and 4 months 
0, 2, and 4 months 
0, 1, 2, and 12 months† 
* All schedules are applicable to single-antigen hepatitis B vaccines; 
Twinrix® (combined hepatitis A and hepatitis B vaccine) may be 
administered at 0, 1, and 6 months. 
† A 4-dose schedule of Engerix-B® is licensed for all age groups. 
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BOX 6. Implementation strategies for adult hepatitis B 
vaccination 
Settings in which a high proportion of persons have 
risk factors for hepatitis B virus (HBV) infection 
• Implement standing orders to administer hepatitis B vac­
cine as part of routine services to all adults who have 
not completed vaccination.* 
Primary care and specialty medical settings 
• Implement standing orders to identify adults recom­
mended for hepatitis B vaccination and administer vac­
cination as part of routine services. 
—	 Provide information to all adults regarding the 
health benefits of hepatitis B vaccination, includ­
ing risk factors for HBV infection and persons for 
whom vaccination is recommended. 
—	 Help adults assess their need for vaccination by ob­
taining a history that emphasizes risks for sexual 
transmission and percutaneous or mucosal expo­
sure to blood. 
—	 Administer hepatitis B vaccine to all adults who re­
port risks for HBV infection.* 
—	 Provide hepatitis B vaccine to all adults seeking pro­
tection from HBV infection. Acknowledgment of 
a specific risk factor for HBV infection is not a re­
quirement for vaccination. 
Occupational health programs 
• Identify staff whose work-related activities involve expo­
sure to blood or other potentially infectious body fluids. 
• Provide education to encourage vaccination. 
• Implement active follow-up, with reminders to track 
vaccine-series completion among persons receiving vac­
cination. 
• Provide appropriate postvaccination testing 1–2 months 
after vaccine-series completion. 
* In populations that have expected high rates of previous HBV infection, 
prevaccination testing might reduce costs by avoiding vaccination of 
persons who are already immune (see Appendix A, Prevaccination 
Serologic Testing for Susceptibility). 
Implementation Strategies 
• In settings in which a high proportion of persons have 
risk factors for HBV infection (Box 7) 
— all adults should be assumed to be at risk for HBV 
infection and should be offered hepatitis B vaccina­
tion if they have not completed a licensed hepatitis B 
vaccine series; 
— health-care providers should implement standing 
orders (244) to administer hepatitis B vaccine as part 
of routine services to adults who have not completed 
the vaccine series and make hepatitis B vaccination a 
standard component of evaluation and treatment for 
STDs and HIV/AIDS (Table 3); and 
BOX 7. Settings in which hepatitis B vaccination is recom­
mended for all adults 
• Sexually transmitted disease treatment facilities 
• Human immunodeficiency virus testing and treatment 
facilities 
• Facilities providing drug-abuse treatment and preven­
tion services 
• Health-care settings targeting services to injection-drug users 
• Correctional facilities 
• Health-care settings targeting services to men who have 
sex with men 
• Chronic-hemodialysis facilities and end-stage renal 
disease programs 
• Institutions and nonresidential day care facilities for 
developmentally disabled persons 
— when feasible, hepatitis B vaccination should be 
offered in outreach and other settings in which ser­
vices are provided to persons at risk for HBV infection 
(e.g., needle-exchange programs, HIV testing sites, 
HIV prevention programs, and homeless shelters). 
• In primary care and specialty medical settings (e.g., 
physician’s offices, family planning clinics, community 
health centers, liver disease clinics, and travel clinics), pro­
viders should implement standing orders to identify adults 
recommended for hepatitis B vaccination and administer 
vaccination as part of routine services. To ensure vaccina­
tion of persons at risk for HBV infection, health-care 
providers should 
— provide information to all adults regarding the health 
benefits of hepatitis B vaccination, including the risk 
factors for HBV infection and persons for whom 
vaccination is recommended; 
— help all adults assess their need for vaccination by 
obtaining a history that emphasizes risks for sexual 
transmission and percutaneous or mucosal exposure 
to blood; 
— administer hepatitis B vaccine to adults who report 
risk factors for HBV infection; and 
— provide hepatitis B vaccine to all adults requesting pro­
tection from HBV infection without requiring 
acknowledgment of a specific risk factor. 
• Occupational health programs should 
— identify all staff whose work-related activities involve 
exposure to blood or other potentially infectious body 
fluids in a health-care, laboratory, public safety, or 
institutional setting (including employees, students, 
contractors, attending clinicians, emergency medical 
technicians, paramedics, and volunteers); 
— provide education to staff to encourage vaccination; 
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TABLE 3. Recommended HIV/AIDS, sexually transmitted disease (STD), and viral hepatitis prevention services, by risk population 
Risk population* Recommended services 
High-risk heterosexuals 
Persons seeking STD evaluation or treatment Hepatitis B vaccination 
Testing for human immunodeficiency virus (HIV) infection† 
Testing for syphilis, gonorrhea, and chlamydia, as clinically indicated§ 
Sexually active men not in a long-term, 
mutually monogamous relationship 
Hepatitis B vaccination 
Annual testing for HIV infection†¶ 
Sexually active women not in a long-term, 
mutually monogamous relationship 
Hepatitis B vaccination** 
Annual testing for HIV infection†¶ 
Annual testing for chlamydia (Note: also recommended for all sexually active females aged <25 yrs)§ 
Men who have sex with men (MSM) 
All MSM Hepatitis A vaccination 
Hepatitis B vaccination** 
Sexually active MSM not in a long-term, 
mutually monogamous relationship 
Hepatitis A vaccination 
Hepatitis B vaccination** 
Annual testing for HIV infection† 
Annual testing for syphilis, gonorrhea, and chlamydia§ 
Injection-drug users Hepatitis A vaccination†† 
Hepatitis B vaccination 
Testing for hepatitis C virus infection§§ 
Annual testing for HIV infection† 
Substance-abuse treatment¶¶ 
* Testing for HIV infection, chlamydia, gonorrhea, syphilis, and hepatitis B surface antigen also is recommended for pregnant women (CDC. Revised 
recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006;55[No. RR-14]; CDC. Sexually 
transmitted diseases treatment guidelines. MMWR 2006;55[No. RR-11]; CDC. A comprehensive immunization strategy to eliminate transmission of 
hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices [ACIP]. Part 1: immunization of 
infants, children, and adolescents. MMWR 2005;54[No. RR-16]).
† CDC. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006;55(No. RR-14).
 
§ CDC. Sexually transmitted diseases treatment guidelines 2006. MMWR 2006;55(No. RR-11).

¶ HIV screening is recommended for all persons aged 13–64 years. Repeat screening is recommended at least annually for persons likely to be at high
 
risk for HIV infection, including MSM or heterosexuals who themselves or whose sex partners have had more than one partner since their most recent 
HIV test. 
** Hepatitis B vaccination is recommended for persons with more than one sex partner during the previous 6 months.
†† CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices 
(ACIP). MMWR 2006;55(No. RR-7).
§§ CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No. RR-19). 
Recommended frequency of testing for hepatitis C virus infection has not been determined.
¶¶ CDC. Substance abuse treatment for injection drug users: a strategy with many benefits. Atlanta, GA: US Department of Health and Human Services, 
CDC; 2002. Available at http://www.cdc.gov/idu/facts/treatment.htm. 
— implement active follow-up, with reminders to track 
completion of the vaccine series among persons 
receiving vaccination; and 
— provide appropriate postvaccination testing 
(Appendix A). 
• Providers in all settings in which hepatitis B vaccine is 
provided should 
— assess patients’ needs for other vaccines recommended 
for adults (schedule available at http://www.cdc.gov/ 
nip/recs/adult-schedule.htm) and administer these 
vaccines at the same office visit at which hepatitis B 
vaccine is administered; 
— identify and vaccinate all susceptible household, sex, 
and needle-sharing contacts of HBsAg-positive per­
sons, and provide HBsAg-positive persons with 
appropriate referrals for counseling and medical man­
agement (Appendix C); 
— provide culturally appropriate materials to educate 
adults about hepatitis B and the importance of vacci­
nation (available at http://www.cdc.gov/ncidod/ 
diseases/hepatitis/b/index.htm#materials); 
— offer vaccination in a way that is accessible, conve­
nient, and flexible for patients; 
— be familiar with ACIP’s general recommendations on 
immunization (210), which provide technical guid­
ance regarding common immunization concerns of 
health-care providers; 
— give persons who are eligible for vaccination a copy 
of the most current vaccine information statement 
for hepatitis B vaccine, as required by federal law 
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(see Appendix A, Hepatitis B Vaccine Dose and 
Administration); 
— institute methods to identify persons with a history of 
vaccination (see Appendix A, Unknown or Uncertain 
Vaccination Status); 
— provide vaccinated persons with a personal record 
card documenting receipt of vaccination (available 
at http://www.immunize.org/guide/aov21_appb_ 
record.pdf ); 
— develop tracking and reminder systems to ensure 
completion of the vaccine series (descriptions of such 
systems are available at http://www.cdc.gov/nip/ 
publications/adultstrat.htm); 
— report adverse events to VAERS using report forms 
and assistance available from CDC at telephone 
1-800-822-7967 or from VAERS at http://www.vaers. 
hhs.gov; and 
— be familiar with billing and reimbursement guidelines 
for hepatitis B vaccination (available at http://www. 
ama-assn.org/ama1/pub/upload/mm/36/ama_hep_ 
coding_trifo.pdf ). 
• Public health agencies and medical organizations should 
educate providers about the benefits of hepatitis B vacci­
nation for their patients and methods to implement and 
support hepatitis B vaccination services in their settings 
and practices. Health departments and community-based 
organizations should increase awareness of the benefits of 
hepatitis B vaccination, particularly among persons at 
increased risk for HBV infection. Educational materials 
are available at http://www.cdc.gov/ncidod/diseases/ 
hepatitis/index.htm. 
• Health departments are encouraged to implement adult 
immunization registries to track the receipt of hepatitis B 
vaccine in all settings in which adults are vaccinated. 
Information on immunization registries is available at 
http://www.cdc.gov/nip/registry. 
• Although hepatitis B vaccination programs aim to achieve 
the highest possible rate of vaccine series completion, con­
cerns regarding completion of the hepatitis B vaccine 
series should not preclude initiation of hepatitis B vacci­
nation. Each dose of vaccine confers some protection 
against HBV infection. Vaccine immunogenicity is not 
decreased by lengthened intradose intervals, and the sec­
ond and third doses can be administered during subse­
quent health-care visits outside of the recommended 
vaccine schedule. 
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Hepatitis B Vaccine Dose 
and Administration 
• Recommended vaccine doses vary by product, age of 
recipient, and needs of special populations (see Table 2). 
Although the antigen contents of vaccines differ, vaccines 
made by different manufacturers are interchangeable for 
all adult schedules. 
• Hepatitis B vaccine should be administered by intramus­
cular injection. The deltoid muscle is the recommended 
site of administration for adults. Injection into the but­
tock is associated with decreased immunogenicity (1–4). 
Intradermal administration can result in a lower sero­
conversion rate and final concentration of antibody to 
hepatitis B surface antigen (anti-HBsAg) compared 
with intramuscular administration; limited data are avail­
able to assess long-term protection from this route of 
administration (5,6). 
• For intramuscular injection, the needle should be long 
enough to reach the muscle mass and prevent vaccine from 
seeping into subcutaneous tissue, but not so long as to 
involve underlying nerves and blood vessels or bone (7). 
The appropriate needle length for adults is 1”–1½” 
(25–38 mm), depending on the recipient’s weight 
(1” [25 mm] for males and females weighing <60 kg 
[<130 lbs]; 1”–1½” [25–38 mm] for females weighing 
60–90 kg [130–200 lbs] and males weighing 60–118 kg 
[130–260 lbs]; and 1½” [38 mm] for females weighing 
>90 kg [>200 lbs] and males weighing >118 kg 
[>260 lbs]). A 22- to 25-gauge needle should be used.* 
• Hepatitis B vaccine administered by any route or site other 
than intramuscularly in the deltoid muscle should not be 
counted as valid and should be repeated unless serologic 
testing indicates that an adequate response has been 
achieved (see Postvaccination Testing for Serologic 
Response). 
• Hepatitis B vaccine and other vaccines administered during 
the same visit should be given in different injection sites. 
• For persons at risk for hemorrhage (e.g., persons with 
hemophilia), the risk for bleeding after intramuscular 
injection can be minimized by using a 23-gauge (or 
smaller) needle, applying direct pressure to the injection 
site for 1–2 minutes, and administering vaccine immedi­
ately after infusion of coagulation factor. Subcutaneous 
administration of vaccine can be considered for these 
persons but might result in lower response and increased 
local reaction. 
• Hepatitis B vaccine should be stored at 35°F–46°F 
(2°C–8oC) and should not be frozen. 
• A vaccine information statement (VIS) must be provided 
to recipients of hepatitis B vaccine. The National Childhood 
Vaccine Injury Act of 1986 (42 U.S.C. § 300aa-26) 
requires vaccine providers to give a copy of the most cur­
rent vaccine-specific VIS to all recipients of vaccines that 
are included on the National Vaccine Injury Compensa­
tion Program table maintained by the Health Resources 
and Services Administration (available at http://www.hrsa. 
gov). Hepatitis B vaccine is included on this table. The 
most current VIS for hepatitis B vaccine is available at 
http://www.cdc.gov/nip/publications/vis. Statements in 
languages other than English are available from the 
Immunization Action Coalition at http://www.immunize.org. 
• Adverse events should be reported to the Vaccine Adverse 
Events Reporting System; report forms and assistance are 
available from CDC at telephone 1-800-822-7967 or at 
http://www.vaers.hhs.gov. 
Hepatitis B Immune Globulin (HBIG) 
Dose and Administration 
• The standard dose of HBIG is 0.06 mL/kg for all 
applications in adults. 
• HBIG may be administered simultaneously with 
hepatitis B vaccine but in a different injection site. 
• HBIG is administered by intramuscular injection. An 
appropriate muscle mass (i.e., deltoid or gluteal) should 
be chosen in which to deliver the large volumes of HBIG 
required by using a needle length appropriate for the 
person’s age and size (7). 
• HBIG should be stored at 35°F–46°F (2°C–8°C) and 
should not be frozen. 
Unknown or Uncertain Vaccination 
Status 
• A reliable vaccination history is defined as a written, dated 
record (e.g., personal, school, physician, or immuniza­
tion registry) of each dose of a complete series. 
* Certain experts recommend a 5/8” (16 mm) needle for males and females 
weighing <60 kg (<130 lbs) (7). 
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• In the majority of clinical practice settings, providers 
should accept only written and dated records as evidence 
of vaccination. Although vaccinations should not be post­
poned if records cannot be located, providers should try 
to locate missing records by contacting previous health-
care providers and asking patients to search for personally 
held records. Persons whose records cannot be located 
should be considered susceptible and started or continued 
on the age-appropriate vaccine schedule. 
• In settings in which written vaccination records are not 
accessible (e.g., sexually transmitted disease [STD] treat­
ment facilities, human immunodeficiency virus [HIV] 
testing facilities, or correctional facilities), an oral history 
of completing a hepatitis B vaccine series can be used to 
defer hepatitis B vaccination. Persons in these settings who 
are uncertain about their vaccination status should be 
vaccinated. Other methods for assessing vaccination his­
tory (e.g., assuming a person received hepatitis B vaccine 
to comply with preschool or middle school entry require­
ments or participation in the U.S. military) might be con­
sidered, but such methods require further research before 
they can be recommended as reliable alternatives. 
• Determining immunity from previous infection through 
serologic testing is an alternative to vaccination. How­
ever, using serologic testing to assess immunity from vac­
cination in persons with unknown or uncertain 
vaccination status can be problematic (see Prevaccination 
Serologic Testing for Susceptibility). 
• Persons who reside in the United States but were vacci­
nated in other countries should be considered fully vacci­
nated if they have written documentation of >3 doses of 
vaccine administered at recommended minimum 
intervals, including the final dose at age >24 weeks. If 
they were not vaccinated according to recommended mini­
mum intervals, they should be revaccinated (see Mini­
mum Dosing Intervals and Management of Persons Who 
Were Vaccinated Incorrectly). Persons without written 
documentation of full vaccination should receive doses 
to complete the age-appropriate vaccine series. 
Interrupted Vaccine Schedules 
• When the hepatitis B vaccine schedule is interrupted, the 
vaccine series does not need to be restarted. 
• If the series is interrupted after the first dose, the second 
dose should be administered as soon as possible, and the 
second and third doses should be separated by an interval 
of at least 8 weeks. 
• If only the third dose has been delayed, it should be ad­
ministered as soon as possible. 
Minimum Dosing Intervals 
and Management of Persons 
Who Were Vaccinated Incorrectly 
• The third dose of vaccine must be administered at least 
8 weeks after the second dose and should follow the first 
dose by at least 16 weeks; the minimum interval between 
the first and second doses is 4 weeks. 
• Inadequate doses of hepatitis B vaccine (see Table 2) or 
doses received after a shorter-than-recommended dosing 
interval should be readministered, using the correct 
dosage or schedule. 
Accelerated Vaccine Schedules 
• The Food and Drug Administration has not approved 
accelerated schedules in which hepatitis B vaccine is 
administered more than once in 1 month. If an accelerated 
schedule (e.g., doses at 0, 7, and 14 days) is used, the patient 
also should receive a booster dose at least 6 months after the 
start of the series to promote long-term immunity. 
Hemodialysis Patients and Other 
Immunocompromised Persons 
• Hepatitis B vaccination is recommended for pre–end-stage 
renal disease patients before they become dialysis depen­
dent and for peritoneal and home dialysis patients 
because they might require in-center hemodialysis. 
• Higher hepatitis B vaccine doses are recommended for 
adult dialysis patients and other immunocompromised 
persons (see Table 2). 
• Serologic testing of hemodialysis patients and other 
immunocompromised persons is recommended 1–2 
months after administration of the final dose of the pri­
mary vaccine series to determine the need for revaccina­
tion (see Postvaccination Testing for Serologic Response). 
In addition, booster doses of vaccine might be needed 
(see Booster Doses). 
Prevaccination Serologic Testing 
for Susceptibility 
• Vaccination of persons who are immune to hepatitis B 
virus (HBV) infection because of current or previous 
infection or vaccination does not increase the risk for 
adverse events. However, in adult populations that have 
expected high rates of previous HBV infection, 
prevaccination testing might reduce costs by avoiding 
vaccination of persons who are already immune (Box). 
Prevaccination testing is recommended for all foreign-born 
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BOX. Method to determine cost-effectiveness of prevac­
cination screening for hepatitis B virus infection when the 
first vaccine dose is administered at the time of blood draw 
Prevaccination testing is cost effective when the cost 
of serologic testing is less than or equal to the cost of 
vaccinating persons who are already immune, as ex­
pressed by the formula 
T <P1 x [P2 + P2(P3)] x v 
where 
T = cost of serologic testing (including cost of blood 
draw); 
P1 = prevalence of previous infection; 
P2 = percentage of recipients of first dose who actually 
receive a second dose; 
P3 = percentage of recipients of doses 1 and 2 who receive 
dose 3; 
[P2 + P2 (P3)] = average number of doses for a person 
starting the series; and 
v = cost per dose of vaccine, including administrative 
costs. 
persons (including immigrants, refugees, asylum seekers, 
and internationally adopted children) born in Africa, Asia, 
the Pacific Islands, and other regions with high endemic­
ity of HBV infection (HBsAg prevalence of >8%) (see 
Figure 4 and Box, Appendix C); for household, sex, and 
needle-sharing contacts of HBsAg-positive persons; and 
for HIV-infected persons (8). In addition, testing might 
be cost effective in adult populations with a prevalence of 
HBV infection of >20% (e.g., injection-drug users, 
incarcerated persons, men who have sex with men; and 
persons born in countries with intermediate levels of 
endemic HBV infection [HBsAg prevalence of 2%–7%] 
[see Figure 4 and Box 2]). In a study conducted in correc­
tional facilities, the cost of prevaccination testing was 
equivalent to vaccination without testing at a threshold 
prevalence of HBV infection of 25% (9). 
• Prevaccination testing can be done with a single test (anti-
HBc) or with a panel of tests (e.g., HBsAg and anti-HBs). 
The typical interpretation of HBV serologic markers has 
been described (see Table 1). 
• When a single test is used, testing for anti-HBc is pre­
ferred because it identifies all persons with previous HBV 
infection, including persons with chronic HBV infection. 
• If prevaccination testing for anti-HBs is used to identify 
immunity after previous HBV infection, HBsAg testing 
also must be performed to identify persons with chronic 
HBV infection. However, for persons who were vacci­
nated previously or whose vaccination status is unknown, 
interpretation of anti-HBs results can be problematic. 
Postvaccination anti-HBs concentrations decline over 
time, and vaccine responders remain protected even when 
anti-HBs concentrations are no longer detectable; there­
fore, a negative anti-HBs result does not necessarily indi­
cate lack of immunity in vaccinated persons. In addition, 
an anti-HBs-positive result can occur even for persons 
who received >1 dose of vaccine but did not complete the 
series. However, long-term protection has been 
demonstrated only for persons who have completed a 
licensed vaccination series and have ever had an anti-HBs 
concentration of >10 mIU/mL; persons with an anti-HBs­
positive result but who did complete a vaccine schedule 
might not have long-term protection from HBV infection. 
• Serologic testing should not be a barrier to vaccination of 
susceptible persons, especially in populations that are dif­
ficult to access. The first vaccine dose typically should be 
administered immediately after collection of the blood 
sample for serologic testing. 
Postvaccination Testing for Serologic 
Response 
• Serologic testing for immunity is not necessary after 
routine vaccination of adults. 
• Testing after vaccination is recommended only for the 
following persons whose subsequent clinical management 
depends on knowledge of their immune status: 
— Health-care workers and public safety workers at high 
risk for continued percutaneous or mucosal exposure 
to blood or body fluids (e.g., acupuncturists, dentists, 
dental hygienists, emergency medical technicians, first 
responders, laboratory technologists/technicians, 
nurses, nurse practitioners, phlebotomists, physicians, 
physician assistants, and students entering these pro­
fessions), to determine the need for revaccination and 
to guide postexposure prophylaxis. Testing persons at 
low risk for continued mucosal or percutaneous 
exposure to blood or body fluids (e.g., public safety 
workers and health-care workers without direct patient 
contact) is not likely to be cost effective. Health-care 
and public safety workers who have written documen­
tation of a complete vaccine series but who have never 
had postvaccination testing do not need serologic test­
ing for anti-HBs unless they have a percutaneous or 
mucosal exposure to blood or body fluids (10). 
— Chronic hemodialysis patients, HIV-infected persons, 
and other immunocompromised persons (e.g., 
hematopoietic stem-cell transplant recipients or per­
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sons receiving chemotherapy), to determine the need 
for revaccination and the type of follow-up testing. 
— Sex partners of HBsAg-positive persons, to determine 
the need for revaccination and for other methods of 
protection against HBV infection. 
• Testing should be performed 1–2 months after adminis­
tration of the last dose of the vaccine series using a method 
that allows determination of a protective concentration 
of anti-HBs (>10 mIU/mL). 
• Persons found to have anti-HBs concentrations of >10 
mIU/mL after the primary vaccine series are considered 
to be immune. 
— Immunocompetent persons have long-term protection 
and do not need further periodic testing to assess anti-
HBs levels. 
— Immunocompromised persons might need annual test­
ing to assess anti-HBs concentrations (see Booster 
Doses). 
• Persons found to have anti-HBs concentrations of <10 
mIU/mL after the primary vaccine series should be 
revaccinated. Administration of 3 doses on an appropri­
ate schedule (see Box 5), followed by anti-HBs testing 
1–2 months after the third dose, usually is more practical 
than serologic testing after 1 or more doses of vaccine. 
• Persons who do not have a protective concentration of 
anti-HBs after revaccination should be tested for HBsAg. 
— If the HBsAg test result is positive, the person should 
receive appropriate management, and any household, 
sex, or needle-sharing contacts should be identified and 
vaccinated (see Appendix C). 
— Persons who test negative for HBsAg should be con­
sidered susceptible to HBV infection and should be 
counseled about precautions to prevent HBV infec­
tion and the need to obtain HBIG postexposure pro­
phylaxis for any known or likely parenteral exposure 
to HBsAg-positive blood (10). 
Booster Doses 
• Booster doses are not recommended for persons with 
normal immune status who were vaccinated as infants, 
children, adolescents, or adults. Serologic testing is not 
recommended to assess antibody concentrations in any 
age group, except in certain circumstances (see Postvacci­
nation Testing for Serologic Response). 
• For hemodialysis patients, the need for booster doses 
should be assessed by annual anti-HBs testing. A booster 
dose should be administered when anti-HBs levels 
decline to <10 mIU/mL. 
• For other immunocompromised persons (e.g., HIV-
infected persons, hematopoietic stem-cell transplant 
recipients, and persons receiving chemotherapy), the need 
for booster doses has not been determined. When anti-
HBs levels decline to <10 mIU/mL, annual anti-HBs test­
ing and booster doses should be considered for persons 
with an ongoing risk for exposure. 
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Appendix B
 
Postexposure Prophylaxis to Prevent Hepatitis B Virus Infection
 
This appendix provides guidelines for management of 
persons with nonoccupational exposure to hepatitis B virus 
(HBV) through a discrete, identifiable exposure to blood or 
body fluids (Table). Guidelines for postexposure prophylaxis 
of occupational exposures have been published separately (1) 
and are intended for use in settings in which postvaccination 
testing is recommended for certain employees (see Appendix 
A, Postvaccination Testing for Serologic Response) and in 
which programs are available to implement testing and fol­
low-up algorithms. Recommendations for management of 
infants born to hepatitis B surface antigen (HBsAg)–positive 
mothers also have been published separately (2). 
HBsAg-Positive Exposure Source 
• Persons who have written documentation of a complete 
hepatitis B vaccine series and who did not receive postvac­
cination testing should receive a single vaccine booster dose. 
• Persons who are in the process of being vaccinated but 
who have not completed the vaccine series should receive 
the appropriate dose of hepatitis B immune globulin 
(HBIG) and should complete the vaccine series. 
• Unvaccinated persons should receive both HBIG and 
hepatitis B vaccine as soon as possible after exposure (pref­
erably within 24 hours). Hepatitis B vaccine may be 
administered simultaneously with HBIG in a separate 
injection site. The hepatitis B vaccine series should be 
completed in accordance with the age-appropriate vac­
cine dose and schedule (see Table 2 and Box 5). 
Exposure Source with Unknown HBsAg 
Status 
• Persons with written documentation of a complete 
hepatitis B vaccine series require no further treatment. 
• Persons who are not fully vaccinated should complete the 
vaccine series. 
• Unvaccinated persons should receive the hepatitis B vac­
cine series with the first dose administered as soon as pos­
sible after exposure, preferably within 24 hours. The 
TABLE. Guidelines for postexposure prophylaxis* of persons with nonoccupational exposures† to blood or body fluids that 
contain blood, by exposure type and vaccination status 
Exposure 
Treatment 
Unvaccinated person§ Previously vaccinated person¶ 
HBsAg**-positive source 
Percutaneous (e.g., bite or needlestick) or mucosal Administer hepatitis B vaccine series and Administer hepatitis B vaccine 
exposure to HBsAg-positive blood or body fluids hepatitis B immune globulin (HBIG) booster dose 
Sex or needle-sharing contact of an HBsAg-positive person Administer hepatitis B vaccine series and Administer hepatitis B vaccine 
HBIG booster dose 
Victim of sexual assault/abuse by a perpetrator who is Administer hepatitis B vaccine series and Administer hepatitis B vaccine 
HBsAg positive HBIG booster dose 
Source with unknown HBsAg status 
Victim of sexual assault/abuse by a perpetrator with Administer hepatitis B vaccine series No treatment 
unknown HBsAg status 
Percutaneous (e.g., bite or needlestick) or mucosal Administer hepatitis B vaccine series No treatment 
exposure to potentially infectious blood or body fluids 
from a source with unknown HBsAg status 
Sex or needle-sharing contact of person with unknown Administer hepatitis B vaccine series No treatment 
HBsAg status 
* When indicated, immunoprophylaxis should be initiated as soon as possible, preferably within 24 hours. Studies are limited on the maximum interval 
after exposure during which postexposure prophylaxis is effective, but the interval is unlikely to exceed 7 days for percutaneous exposures or 14 days 
for sexual exposures. The hepatitis B vaccine series should be completed.
† These guidelines apply to nonoccupational exposures. Guidelines for management of occupational exposures have been published separately (1) and 
also can be used for management of nonoccupational exposures, if feasible.
§ A person who is in the process of being vaccinated but who has not completed the vaccine series should complete the series and receive treatment as 
indicated. 
¶ A person who has written documentation of a complete hepatitis B vaccine series and who did not receive postvaccination testing. 
** Hepatitis B surface antigen. 
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vaccine series should be completed in accordance with 
the age-appropriate dose and schedule (see Table 2 and 
Box 5). 
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Appendix C 
Identification and Management of Hepatitis B
 
Surface Antigen (HBsAg)–Positive Persons
 
Persons with chronic hepatitis B virus (HBV) infection are 
at high risk for chronic liver disease and are a major reservoir 
of HBV infection. Foreign-born populations from Africa, Asia, 
and the Pacific Islands have high rates of chronic HBV infec­
tion (i.e., HBsAg prevalence of >8%). During delivery of rec­
ommended hepatitis B vaccination services (e.g., HBsAg 
screening of pregnant women and serologic testing to assess 
susceptibility), vaccination providers will identify persons who 
are HBsAg positive. These persons require counseling and 
medical management for chronic HBV infection to reduce 
their risk for chronic liver disease. Their susceptible house­
hold, sex, and needle-sharing contacts also should be vacci­
nated against hepatitis B. 
Extending screening, referral, and contact vaccination ser­
vices to persons identified as HBsAg positive can help prevent 
serious sequelae in persons with chronic infection and enhance 
vaccination strategies to eliminate HBV transmission. This 
appendix provides guidance for vaccination providers concern­
ing identification and management of persons with chronic 
HBV infection. These guidelines are not intended to repre­
sent a comprehensive prevention program for persons with 
chronic infection. 
Identification of Persons Who Are 
Potentially HBsAg Positive 
• All foreign-born persons (including immigrants, refugees, 
asylum seekers, and internationally adopted children) from 
Africa, Asia, the Pacific Islands, and other regions with 
high endemicity of HBV infection (Box) should be tested 
for HBsAg, regardless of vaccination status. 
— For all persons born in countries in which HBV is 
highly endemic who are applying for permanent U.S. 
residence, HBsAg screening and appropriate follow-
up on the basis of HBsAg test results should be 
included as part of the required overseas premigration 
and domestic adjustment-of-visa status medical exami­
nation process; information about this process is avail­
able at http://www.cdc.gov/ncidod/dq/health.htm. 
HBsAg-positive persons should be considered eligible 
for migration and adjustment-of-visa status and coun­
seled and recommended for follow-up medical evalua­
tion and management in U.S. resettlement communities. 
— In all settings that provide health care, providers should 
identify persons born in countries in which HBV infec-
BOX. Geographic regions* with high† hepatitis B virus 
endemicity 
Africa: all countries except Algeria, Djibouti, Egypt, 
Libya, Morocco, and Tunisia 
Southeast Asia: all countries except Malaysia 
East Asia: China, Hong Kong, Mongolia, North Korea, 
South Korea, and Taiwan 
Australia and South Pacific: all countries except 
Australia, Guam, and New Zealand 
Middle East: Jordan and Saudi Arabia 
Eastern Europe and Northern Asia: Albania, Armenia, 
Azerbaijan, Bulgaria, Croatia, Georgia, Kazakhstan, 
Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and 
Uzbekistan 
Western Europe: Malta and indigenous populations in 
Greenland 
North America: Alaska Natives and indigenous 
populations in Northern Canada 
South America: Amazonian areas of Bolivia, Brazil, 
Columbia, Peru, and Venezuela 
Caribbean: Turks and Caicos 
* A complete list of countries in each region is available at http://www.cdc. 
gov/travel/destinat.htm. 
† Hepatitis B surface antigen prevalence of >8%. 
tion is highly endemic and provide HBsAg testing and 
follow-up. Retesting of persons who were tested for 
HBsAg in other countries should be considered. 
• Other persons who should be tested for HBsAg as part of 
vaccination services include 
— all pregnant women (1); 
— persons who receive prevaccination testing for suscep­
tibility and who test positive for anti-HBc (see 
Appendix A, Prevaccination Serologic Testing for 
Susceptibility); 
— hemodialysis patients; and 
— nonresponders to vaccination (see Appendix A, Post­
vaccination Testing for Serologic Response). 
Management of Persons Identified 
as HBsAg Positive 
• All HBsAg-positive laboratory results should be reported 
to the state or local health department, in accordance with 
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state requirements for reporting of chronic HBV infec­
tion; information about state requirements is available at 
http://www.cste.org/NNDSSSurvey/2004NNDSS/ 
nndssstatechrreporcond2005.asp. 
• HBsAg-positive persons should be referred for evaluation to 
a physician experienced in the management of chronic liver 
disease; a directory of liver specialists is available at 
http://www.hepb.org/resources/other_links_physician.htm. 
Certain patients with chronic HBV infection will benefit 
from early intervention with antiviral treatment, manage­
ment of factors that can contribute to disease progres­
sion, or screening to detect hepatocellular carcinoma at an 
early stage. 
• Household, sex, and needle-sharing contacts of HBsAg­
positive persons should be identified. Unvaccinated sex 
partners and household and needle-sharing contacts 
should be tested for susceptibility to HBV infection (see 
Appendix A, Prevaccination Serologic Testing for Suscep­
tibility) and should receive the first dose of hepatitis B 
vaccine immediately after collection of blood for sero­
logic testing. Susceptible persons should complete the 
vaccine series using an age-appropriate vaccine dose and 
schedule (see Table 2 and Box 5). Persons who are not 
fully vaccinated should complete the vaccine series. 
• Sex partners of HBsAg-positive persons should be coun­
seled to use methods (e.g., condoms) to protect them­
selves from sexual exposure to infectious body fluids (e.g., 
semen or vaginal secretions) unless they have been dem­
onstrated to be immune after vaccination (i.e., antibody 
to HBsAg concentrations of >10 mIU/mL) or previously 
infected (anti-HBc positive). Partners should be made 
aware that use of condoms and other prevention meth­
ods might reduce their risks for human immunodeficiency 
virus (HIV) and other sexually transmitted diseases 
(STDs). 
• To prevent or reduce the risk for transmission to others, 
HBsAg-positive persons should be advised concerning the 
risks for 
— perinatal transmission to infants born to HBsAg­
positive women and the need for such infants to 
receive hepatitis B vaccine beginning at birth (1) and 
— transmission to household, sex, and needle-sharing 
contacts and the need for such contacts to receive hepa­
titis B vaccine. 
• HBsAg-positive persons should also be advised to 
— notify their sex partners about their status; 
— use methods (e.g., condoms) to protect nonimmune 
sex partners from acquiring HBV infection from sexual 
activity until the sex partners can be vaccinated and 
their immunity documented (persons should be made 
aware that use of condoms and other prevention meth­
ods might reduce their risks for HIV and other STDs); 
— cover cuts and skin lesions to prevent spread through 
infectious secretions or blood; 
— refrain from donating blood, plasma, tissue, or semen 
(organs may be donated to HBV-immune or chroni­
cally infected persons needing a transplant; decisions 
about organ donation should be made on an individual 
basis); and 
— refrain from sharing household articles (e.g., tooth­
brushes, razors, or personal injection equipment) that 
could become contaminated with blood. 
• To protect the liver from further harm, HBsAg-positive 
persons should be advised to 
— avoid or limit alcohol consumption because of the 
effects of alcohol on the liver; 
— refrain from taking any new medicines, including over­
the-counter and herbal medicines, without consulting 
with their health-care provider; and 
— obtain vaccination against hepatitis A if chronic liver 
disease is present (2). 
• When seeking medical or dental care, HBsAg-positive 
persons should be advised to inform those responsible for 
their care of their HBsAg status so that they can be evalu­
ated and their care managed appropriately. 
• Other counseling messages include the following: 
— HBV is not spread by breastfeeding, kissing, hugging, 
coughing, ingesting food or water, sharing eating uten­
sils or drinking glasses, or casual contact. 
— Persons should not be excluded from work, school, 
play, child care, or other settings on the basis of their 
HBsAg status, unless they are prone to biting (3). 
— Involvement with a support group might help patients cope 
with chronic HBV infection. Information about support 
groups is available at http://www.hepprograms.org/support/ 
hepb.asp and http://www.hepb.org/patients/support_ 
groups.htm. 
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1.	 In which settings is universal hepatitis B vaccination recommended 
because of the high proportion of adults with behavioral risk factors 
for HBV infection? 
A.	 Sexually transmitted disease and human immunodeficiency virus 
(STD/HIV) testing and treatment facilities. 
B.	 Drug-abuse treatment and prevention settings. 
C.	 Health-care settings targeting services to men who have sex with men 
(MSM). 
D. Correctional facilities. 
E.	 Hospitals. 
2.	 The Advisory Committee on Immunization Practices (ACIP) 
recommends standing orders to identify adults recommended for 
hepatitis B vaccination and administer vaccination as part of routine 
services in primary care and specialty medical settings. 
A.	 True. 
B.	 False. 
3.	 Which of the following practices should be implemented in primary 
care and specialty medical settings to ensure vaccination of adults at 
risk for HBV infection? (Indicate all that apply.) 
A.	 Provide information to all adults regarding the benefits of hepatitis B 
vaccination, including the risk factors for HBV infection and persons 
for whom vaccination is recommended. 
B.	 Help adults assess their need for vaccination by obtaining a history that 
emphasizes risks for sexual transmission and percutaneous or mucosal 
exposure to blood. 
C.	 Provide hepatitis B vaccine to persons who report risk factors for HBV 
infection. 
D.	 Request that adults acknowledge a specific factor for HBV infection 
before offering hepatitis B vaccine. 
4.	 Which of the following are components of a successful adult hepatitis 
B vaccination program? (Indicate all that apply.) 
A.	 Protocols and standing orders. 
B.	 Protected patient confidentiality. 
C.	 Trained and knowledgeable staff. 
D. Funding for vaccine. 
E.	 Billing and reimbursement mechanisms. 
5.	 Which of the following persons are recommended to receive hepatitis 
B vaccine because they have a risk factor for HBV infection? (Indicate 
all that apply.) 
A.	 Sexually active persons who are not in a long-term, mutually 
monogamous relationship. 
B.	 Injection-drug users. 
C.	 MSM. 
D. Persons who live in a household with a person who is hepatitis B surface 
antigen (HBsAg)–positive. 
E.	 Persons seeking treatment for an STD. 
F.	 Pregnant women. 
6.	 Which of the following statements regarding hepatitis B vaccination 
are true? (Indicate all that apply.) 
A.	 Hepatitis B vaccine is available as a single-antigen formulation only. 
B.	 Primary vaccination against hepatitis B consists of 3 doses 
administered at 0, 1, and 6 months. 
C.	 Increasing the interval between the first 2 doses has little effect on 
immunogenicity or final antibody concentration. 
D.	 Differences in immunogenicity have been observed when hepatitis B 
vaccines produced by different manufacturers are used to complete the 
vaccine series. 
E.	 Routine vaccination of adults should be followed by postvaccination 
testing to determine serologic response. 
7.	 Which of the following statements regarding immune memory for 
hepatitis B are true? (Indicate all that apply.) 
A.	 Antibody to HBsAg (anti-HBs) is the only easily measurable correlate 
of vaccine-induced protection. 
B.	 After primary vaccination with hepatitis B vaccine, anti-HBs 
concentrations decline rapidly within the first year. 
C.	 When anti-HBs concentrations decline to <10 mIU/mL, all 
vaccinated persons should receive a booster dose of hepatitis B vaccine. 
D.	 A booster dose of hepatitis B vaccine is recommended 10 years after the 
3rd dose of vaccine was received. 
8.	 Which of the following statements regarding hepatitis B immune 
globulin (HBIG) are true? (Indicate all that apply.) 
A.	 HBIG provides temporary protection when administered in standard 
doses. 
B.	 HBIG typically is used instead of hepatitis B vaccine for postexposure 
immunoprophylaxis to prevent HBV infection. 
C.	 No evidence exists that HBV, hepatitis C virus, or HIV have ever been 
transmitted by HBIG in the United States. 
D. HBIG administered alone is the primary means of protection after an 
HBV exposure for nonresponders to hepatitis B vaccination. 
9.	 Postvaccination testing is recommended for which of the following 
populations? (Indicate all that apply.) 
A.	 Certain health-care and public safety workers. 
B.	 Chronic hemodialysis patients. 
C.	 HIV-infected persons. 
D. HCV-infected persons. 
E.	 Sex partners of HBsAg-positive persons. 
10. Which best describes your professional activities? 
A.	 Physician. 
B.	 Nurse. 
C.	 Health educator. 
D. Office staff. 
E.	 Other. 
11. I plan to use these recommendations as the basis for… (Indicate all 
that apply.) 
A.	 health education materials. 
B.	 insurance reimbursement policies. 
C.	 local practice guidelines. 
D. public policy. 
E.	 other. 
12. Overall, the length of the journal report was… 
A. much too long. 
B. a little too long. 
C. just right. 
D. a little too short. 
E. much too short. 
13. After reading this report, I am confident I can identify adults who are 
recommended to receive hepatitis B vaccination. 




E. Strongly disagree. 
14. After reading this report, I am confident I can identify settings in 
which a high proportion of persons are likely to be at risk for HBV 
infection. 




E. Strongly disagree. 
15. After reading this report, I am confident I can identify components of 
a successful adult hepatitis B vaccination program. 




E. Strongly disagree. 
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16. After reading this report, I am confident I can identify strategies to 
increase vaccination coverage among adults at risk for HBV infection. 




E. Strongly disagree. 
17. After reading this report, I am confident I can describe practices that 
should be implemented in settings in which adults receive hepatitis B 
vaccine. 




E. Strongly disagree. 
18. After reading this report, I am confident I can describe adult 
vaccination schedules. 




E. Strongly disagree. 
19. The learning outcomes (objectives) were relevant to the goals of this 
report. 




E. Strongly disagree. 
(Continued on pg CE-4) 
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20. The instructional strategies used in this report (text, tables, figures, 
boxes, and appendices) helped me learn the material. 




E. Strongly disagree. 
21. The content was appropriate given the stated objectives of the report. 




E. Strongly disagree. 
22. The content expert(s) demonstrated expertise in the subject matter. 




E. Strongly disagree. 
23. Overall, the quality of the journal report was excellent. 




E. Strongly disagree. 
24. These recommendations will improve the quality of my practice. 




E. Strongly disagree. 
25. The availability of continuing education credit influenced my 
decision to read this report. 




E. Strongly disagree. 
26. The MMWR format was conducive to learning this content. 




E. Strongly disagree. 
27. Do you feel this course was commercially biased? (Indicate yes or no; 
if yes, please explain in the space provided.) 
A. Yes. 
B. No. 
28. How did you learn about the continuing education activity? 
A. Internet. 
B. Advertisement (e.g., fact sheet, MMWR cover, newsletter, or journal). 
C. Coworker/supervisor. 
D. Conference presentation. 
E. MMWR subscription. 
F. Other. 
Correct answers for questions 1–9. 
A, B, C, and D. 2. A. 3. A, B, and C. 4. A, B, C, D, and E. 5. A, B, C, D, 1.
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